How to Find Clinical Trials for Experimental Cancer Treatments The New York Times Health Dec 23, 2016
"FDA gave accelerated approval to atezolizumab injection (Tecentriq, Genentech, Inc.) for the treatment of patients with locally advanced or metastatic urothelial carcinoma who have disease progression during or following platinum-containing chemotherapy or have disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy. Atezolizumab is a programmed death-ligand 1 (PD-L1) blocking antibody. More Information. May 18, 2016"
"For more than 100 years, immunology and immunotherapy have played an ever-increasing role in the understanding and treatment of cancer. Since 1953, CRI and CRI scientists have played a major role in bringing about and accelerating this transformation. Our timeline, spanning 1891 to today and containing more than 200 entries, shows some of the major discoveries and milestones in the field, highlighting CRI's impact along the way."
Science Snaps: understanding where breast cancer stems from Cancer Research UK
SELECTED ONCOLOGY PUBLICATIONS 2018
Atezolizumab provides long-term lung cancer survival benefit Healio HemOnc Today April 12, 2018
"Enhanced understanding how cancer evolves to metastases http://www.cell.com/cell/fulltext/S0092-8674(18)30389-1 … @CellCellPress @CellPressNews importance of "bottlenecking" and diminished role of driver mutations; rapid vs "attenuated" progression" Eric Topol 04/12
Tracking Cancer Evolution Reveals Constrained Routes to Metastases: TRACERx Renal Cell DOI: https://doi.org/10.1016/j.cell.2018.03.057
SELECTED ONCOLOGY PUBLICATIONS 2017
New breast cell types discovered by multidisciplinary research team MedicalXpress November 20, 2017
Cancer Evolution: No Room for Negative Selection Cell Volume 171, Issue 5, p987–989, 16 November 2017
Comprehensive Analysis of Hypermutation in Human Cancer Cell Volume 171, Issue 5, p1042–1056.e10, 16 November 2017
PD-L1 genetic overexpression or pharmacological restoration in hematopoietic stem and progenitor cells reverses autoimmune diabetes Science Translational Medicine 15 Nov 2017
A Zombie Gene Protects Elephants From Cancer Wired 11/12/2017
Fighting cancer with cancer: 3-D cultured cells could drive precision therapy MedicalXpress November 8, 2017
Stress hormones promote EGFR inhibitor resistance in NSCLC: Implications for combinations with b-blockers Sci. Transl. Med. 9, eaao4307 (2017) 8 November 2017
Identification of unique neoantigen qualities in long-term survivors of pancreatic cancer Nature 08 November 2017
A neoantigen fitness model predicts tumour response to checkpoint blockade immunotherapy Nature 08 November 2017
Cancer research – how a traffic jam causes tumor growth MedicalXpress November 7, 2017
Association of Warfarin Use With Lower Overall Cancer Incidence Among Patients Older Than 50 Years JAMA Internal Medecine November 6, 2017
Evolution and clinical impact of co-occurring genetic alterations in advanced-stage EGFR-mutant lung cancers Nature Genetics November 6, 2017
Scalable whole-exome sequencing of cell-free DNA reveals high concordance with metastatic tumors Nature Communications 06 November 2017
Researchers connect two important signalling pathways in cancer and ageing for the first time MedicalXpress November 3, 2017
Scientists link pancreatic cancer survival to four genes MedicalXpress November 3, 2017
Your gut bacteria could determine how you respond to cutting-edge cancer drugs Science Nov. 2, 2017
Future cancer research priorities in the USA: a Lancet Oncology Commission The Lancet Oncology Volume 18, No. 11, e653–e706, November 2017
Scientists discover surprising immune cell activity that may be limiting immunotherapy MedicalXpress October 30, 2017
Computer programme could predict if immunotherapy will work Cancer Research UK 27 October 2017
Allele-Specific HLA Loss and Immune Escape in Lung Cancer Evolution Cell October 26, 2017
Nerves switch on angiogenic metabolism Science 20 Oct 2017
"Nerves release neurotransmitters to regulate most physiologic functions in the body. Recently, it has been recognized that nerves play dominant roles in organogenesis and tissue regeneration (1, 2). In addition, growing evidence suggests that cancer development in a variety of tissues is controlled by an assortment of nerve-mediated signals, including neurotransmitters and other molecules (3–5).""
Adrenergic nerves activate an angio-metabolic switch in prostate cancer Science 20 Oct 2017
"We've long known blood vessels are key to cancer progression, but then there's nerves" Eric Topol
Obesity linked to 13 types of cancer (Update) MedicalXpress October 3, 2017
More information: Farhad Islami, M.D., Ph.D., strategic director, cancer surveillance research, American Cancer Society; Oct. 3, 2017, media briefing with Anne Schuchat, M.D., deputy director, and Lisa Richardson, M.D., M.P.H., director, division of cancer prevention and control, both U.S. Centers for Disease Control and Prevention; Oct. 3, 2017, CDC's Morbidity and Mortality Weekly Report, online.
Targeting the renin-angiotensin system to improve cancer treatment: Implications for immunotherapy Science Translational Medicine 04 Oct 2017
"When drugs used for blood pressure can help rev up the immune system against cancer: a review" Eric Topol
Tobacco smokers could gain 86 million years of life if they switch to vaping, study finds MedicalXpress October 2, 2017
More information: Potential deaths averted in USA by replacing cigarettes with e-cigarettes, Tobacco Control, DOI: 10.1136/tobaccocontrol-2017-053759
New system finds and targets vulnerabilities in lung cancer cells MedicalXpress October 2, 2017
More information: Keap1 loss promotes Kras-driven lung cancer and results in dependence on glutaminolysis, Nature Medicine (2017). nature.com/articles/doi:10.1038/nm.4407
"Topology of cancer:" Eric Topol
1. 3D of whole tissue biopsy Whole-tissue biopsy phenotyping of three-dimensional tumours reveals patterns of cancer heterogeneity Nature Biomedical Engineering (2017)
2. Nuclear architecture Nuclear topology modulates the mutational landscapes of cancer genomes Nature Structural & Molecular Biology 2(2017)
HPV and cancer: Key mechanism may suggest treatment MedicalNewsToday October 2, 2017
"Two studies suggest that vitamin C is important for the tumour suppressor function of TET in acute myeloid leukaemia":
Beyond the C Nature Reviews Drug Discovery 16, 678-679, 2017
"Vitamin C (vitC) has shown only limited benefit in the treatment of solid malignancies. Now, two groups have independently reported that in mice, vitC can help suppress haematological malignancies such as acute myeloid leukaemia (AML). Their observations were at least partly dependent on the presence of the gene Tet methylcytosine dioxygenas…"
Immunotherapy Response Predicted by Liquid Biopsy GEN News Highlights October 2, 2017
Biologists identify possible new strategy for halting brain tumors MedicalXpress September 29 (2017)
More information: Christian J. Braun et al. Coordinated Splicing of Regulatory Detained Introns within Oncogenic Transcripts Creates an Exploitable Vulnerability in Malignant Glioma, Cancer Cell (2017). DOI: 10.1016/j.ccell.2017.08.018
Anti-inflammatory drug cuts risk of heart disease — and cancer Nature Reviews Drug Discovery 16, 665-667 (2017)
Interactions between the tumor and the blood systemic response of breast cancer patients PLOS Computational Biology September 28, 2017
"How to understand the immune response to breast cancer? Call in your computational biologists" Eric Topol
Single-Cell Analysis of Human Pancreas Reveals Transcriptional Signatures of Aging and Somatic Mutation Patterns Cell Volume 171, Issue 2, p321–330.e14, 5 October 2017
"Omic dissection of the human pancreas, one cell at a time" Eric Topol
Editing genes one by one throughout colorectal cancer cell genome uncovers new drug target MedicalXPress September 27, 2017
"The team used the CRISPR-Cas9 gene editing technique to systematically inactivate every gene in the genome of human colorectal cancer cells with and without mutant KRAS. They found that growth of KRAS-mutant colorectal cancer cells in mice was reduced by approximately 50 percent when two genes that encode metabolic enzymes—NADK and KHK—were also inactivated."
Chimeric antigen receptor T-cell therapy - assessment and management of toxicities NATURE REVIEWS CLINICAL ONCOLOGY September 19, 2017
MRI agent distinguishes aggressive from slow-growing breast cancer Drug Target Review 25 September 2017
Tragedy, Perseverance, and Chance — The Story of CAR-T Therapy NJEM 2017, 377, 1313-1315
"The emergence of CAR-T therapy reflects the incremental insights of hundreds of scientists over decades."
Chromosome 1q21.3 amplification is a trackable biomarker and actionable target for breast cancer recurrence Nature Medecine 25 September 2017
"So many new biomarkers are of questionable value. But this one (aCNV) for breast cancer recurrence looks impressive" Eric Topol
"A new blood test shows promise for detecting pancreatic cancer at its earliest stages"
Australian researchers say they can stop melanoma spreading MedicalXpress September 11, 2017
"These clinical trials show we now have ammunition to prevent melanoma spreading and progressing, which until now was a critical area of disease behaviour where we had no control," said Long.
"This will change how melanoma is treated around the world, as we no longer have to passively wait to see if the melanoma spreads."
1. Long G.V, et al. Adjuvant Dabrafenib Plus Trametinib for Stage III BRAF-Mutated Melanoma. New England Journal of Medicine.
2. Weber, J. et al. Adjuvant Nivolumab Versus Ipilimumab in Resected Stage III or IV Melanoma. New England Journal of Medicine.
A pen that detects cancerous tissue could help surgeons remove the full tumor STAT By Kate Sheridan September 6, 2017
More information: Nondestructive tissue analysis for ex vivo and in vivo cancer diagnosis using a handheld mass spectrometry system Science Translational Medicine 06 Sep 2017 Vol. 9, Issue 406
"Tumor infiltrating lymphocytes (TILs) levels emerging as marker for higher response to immunotherapy" Michael Misialek MD
"Sherene Loi, Lab Head and Medical Oncologist of the Peter MacCallum Cancer Center in Melbourne, Australia, investigated TILs, which have been observed in TNBC and may represent pre-existing antitumour immunity, as a biomarker for response to immunotherapy in TNBC."
Beyond the C by Ulrike Harjes Nature Reviews Cancer 08 September 2017
"Two studies report that vitamin C can reduce Tet-dependent leukaemia progression in mice Nature Review Cancer 2017"
FDA approval brings first gene therapy to the United States - CAR T-cell therapy approved to treat certain children and young adults with B-cell acute lymphoblastic leukemia. August 30, 2017
"The FDA approved Kymriah (tisagenlecleucel) for certain pediatric and young adult patients with a form of acute lymphoblastic leukemia (ALL).
“We’re entering a new frontier in medical innovation with the ability to reprogram a patient’s own cells to attack a deadly cancer,” said FDA Commissioner Scott Gottlieb, M.D. “New technologies such as gene and cell therapies hold out the potential to transform medicine and create an inflection point in our ability to treat and even cure many intractable illnesses. At the FDA, we’re committed to helping expedite the development and review of groundbreaking treatments that have the potential to be life-saving.”
Kymriah, a cell-based gene therapy, is approved in the United States for the treatment of patients up to 25 years of age with B-cell precursor ALL that is refractory or in second or later relapse."
""At Novartis, we have a long history of being at the forefront of transformative cancer treatment," said Joseph Jimenez, CEO of Novartis. "Five years ago, we began collaborating with the University of Pennsylvania and invested in further developing and bringing what we believed would be a paradigm-changing immunocellular therapy to cancer patients in dire need. With the approval of Kymriah, we are once again delivering on our commitment to change the course of cancer care."
"We are so proud to be part of this historic moment in cancer treatment and are deeply grateful to our researchers, collaborators, and the patients and families who participated in the Kymriah clinical program," said Bruno Strigini, CEO of Novartis Oncology. "As a breakthrough immunocellular therapy for children and young adults who desperately need new options, Kymriah truly embodies our mission to discover new ways to improve patient outcomes and the way cancer is treated.""
Breakthrough in better understanding of acute myeloid leukaemia Drug Target Review 25 May 2017
"Keytruda (pembrolizumab) is indicated for the treatment of adult and pediatric patients with unresectable or metastatic solid tumors that have been identified as having a biomarker referred to as microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR)."
Cigarette filters may increase lung cancer risk Reuters Health News Mon May 22, 2017
Cigarette Filter Ventilation and its Relationship to Increasing Rates of Lung Adenocarcinoma J Natl Cancer Inst (2017)
"On April 28, the Food and Drug Administration (FDA) granted accelerated approval to the targeted therapy brigatinib (Alunbrig™) for patients with metastatic non-small cell lung cancer (NSCLC) and alterations in the ALK gene whose cancer has progressed during their initial therapy."
Regorafenib Clinically Active in Ewing Sarcoma Cancer Therapy Advisor May 19, 2017
See: Attia S, Bolejack V, Ganjoo KN, et al. A phase II trial of regorafenib (REGO) in patients (pts) with advanced Ewing sarcoma and related tumors (EWS) of soft tissue and bone: SARC024 trial results. J Clin Oncol. 2017;35(suppl; abstr 11005).
Lung Cancer: A Wily Genetic Opponent Cell Volume 169, Issue 5, p777–779, 18 May 2017
"Smart essay on tumor heterogeneity & plasma ctDNA, dealing w/ heterogeneity" Eric Topol
Scientists to test whether Zika can kill brain cancer cells Reuters Science News Fri May 19, 2017
Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K–mutant melanoma: long-term survival and safety analysis of a phase 3 study Annals of Oncology 05 May 2017
"Long term OS data with dabrafenib-trametinib in malignant melanoma: as good as immunotherapy?" Prof Soria Medical Oncologist
Do you know the differences between CDK4 and CDK6 in breast cancer? Lilly Oncology 2017
"Recent evidence suggests CDK4 & CDK6 roles differ, such as preferential activity in epithelial (CDK4) vs mesenchymal (CDK6) cancers." Cancer Medicine
Chromatin states define tumour-specific T cell dysfunction and reprogramming Nature 25 May 2017
"Cancer immunoRx biology advanced w/ 2 new Nature papers: Tumor specific T-cells and Macrophages" Eric Topol
Vaccine may cut HPV infections, an oral cancer risk, in men MedicalXpress May 17, 2017
"The trial studied imatinib, known commonly under the brand name Gleevec2, in 62 patients with severe and difficult-to-treat asthma. Imatinib is a chemotherapy used to treat leukemia and other cancers."
The genetic microscope Nature 18 May 2017
"Single-cell genomic sequencing is poised to revolutionize fields from cancer to immunology."
"Nice summary of the impact of single cell genomics in cancer and immunology research" Eric Topol
Celgene leukemia drug extends survival in early stage trial Reuters Health May 18, 2017
Cancer Stat Facts: Colon and Rectum Cancer NCI 2017 "Colorectal Cancer has a 64.9% 5-year survival rate."
Scientists light the way for immune system to attack cancer Drug Target Review 15 May 2017
Declining Incidence Rates of Prostate Cancer in the United States Is This Good News or Not? JAMA Oncology May 11, 2017
"Is the diminishing incidence of prostate cancer good news? JAMAOnc Confusion abounds: vis-a-vis NEJM summary March 30 2017" Eric Topol
A lead candidate for immunotherapy may increase tumour growth in certain cancers MedicalXpress May 12, 2017
U.S. FDA approves Merck immunotherapy/chemo combo for lung cancer Reuters Health News May 11, 2017
Treating Cancer: Hope Vs. Hype - Dozens Of New Cancer Drugs Do Little To Improve Survival, Frustrating Patients KHN February 9, 2017
Roche's star cancer drug stumbles in study, raising doubts about future Reuters Health May 10, 2017
"Roche's Tecentriq immuno-oncology drug failed a late-stage follow-up trial against advanced bladder cancer, the Swiss drugmaker said on Wednesday, raising questions about whether regulators could scale back their approval of the medicine."
Scrib protein identified as a natural suppressor of liver cancer Drug Target Review 8 May 2017
Platelets suppress T cell immunity against cancer EurekAlert! May 2017
"Blood platelets help disguise cancer from the immune system by suppressing T cells, report scientists at the Medical University of South Carolina (MUSC) in the May 5, 2017 issue of Science Immunology. In extensive preclinical tests, a promising T cell therapy more successfully boosted immunity against melanoma when common antiplatelet drugs such as aspirin were added."
Aspirin Prevents Platelets from Suppressing Anticancer T Cells GEN News Highlights May 8, 2017
Tracking the Evolution of Non–Small-Cell Lung Cancer NEJM April 26, 2017
"We wanted to prospectively investigate intratumor heterogeneity in relation to clinical outcome and to determine the clonal nature of driver events and evolutionary processes in early-stage NSCLC."
Ovarian Cancer Epidemiology Roche May 7, 2017
"Despite much progress in fighting ovariancancer, it remains the most deadly of all cancers that affect women"
Surprising link between blood sugar and brain cancer found MedicalXpress May 3, 2017
""Diabetes and elevated blood sugar increase the risk of cancer at several sites including the colon, breast and bladder. But in this case, these rare malignant brain tumors are more common among people who have normal levels of blood glucose than those with high blood sugar or diabetes," Schwartzbaum said."
Regular use of aspirin can lower risk of breast cancer for women ecancernews 02 May 2017
"A City of Hope-led study found that the use of low-dose aspirin (81mg) reduces the risk of breast cancer in women who are part of the California's Teacher's Study."
U.S. FDA approves Takeda's lung cancer drug as second-line treatment Reuters Health News Apr 28, 2017
"The drug, Alunbrig (Ariad), is approved as a second-line treatment for patients with anaplastic lymphoma kinase-positive (ALK+) metastatic non-small cell lung cancer, who have progressed on or are intolerant to Pfizer's crizotinib, the standard initial treatment for the disease."
CAR T therapies drive into new terrain Nature Reviews Drug Discovery 28 April 2017
"The FDA could soon approve the first chimeric antigen receptor (CAR) T therapies for blood cancers, but this young field is still working on how to address solid tumours, safety concerns and manufacturing issues."
U.S. FDA approves Novartis' leukemia treatment Reuters Health Apr 28, 2017
"Rydapt is approved to be used along with chemotherapy to treat adults newly diagnosed with AML and carrying a specific genetic mutation called FLT3, the FDA said. It is to be used along with a companion diagnostic designed to detect the mutation."
Health Effects of Cigarette Smoking CDC 2017
RNA editing-dependent epitranscriptome diversity in cancer stem cells Nature Reviews Cancer 18 April 2017
"NEW Review out now: The roles of deregulated RNA processing in cancer stem cells by Jamieson"
James Allison Has Unfinished Business with Cancer MIT Technology Review April 24, 2017
"Why do most patients fail to respond to the newest cures?"
"The drug he identified to do that, called Yervoy, went on sale in 2011 to treat metastatic skin cancer. In lucky patients, it causes otherwise fatal tumors to melt away. By last year, worldwide sales of Yervoy and two newer drugs had reached $6 billion a year, and the medications had been given to more than 100,000 people. This transformative new class of immunotherapy agents, known as checkpoint inhibitors, is acknowledged to be the most important advance against cancer since chemotherapy."
Lilly reports positive interim data on breast cancer combo drug Reuters Health Apr 24, 2017
"The study, named Monarch-3, compared combined use of abemaciclib and an aromatase inhibitor with the aromatase inhibitor alone."
Novel miRNA-mRNA interactions conserved in essential cancer pathways Sci Rep 2017; 7: 46101
"Study of 15 TCGA tumor types found novel miRNA-mRNA interactions conserved in essential cancer pathways" NCI Genomics
The Potential for Immunotherapy in Pancreatic Cancer OncLive Mar 23, 2017
"So much to it, so much more to learn: cancer Rx efficacy interaction with the gut microbiome" Eric Topol
Can Histone Deacetylase Inhibitors Reverse Resistance to Angiogenesis Inhibitors? The ASCO POST 3/7/2017
See: Inhibiting Histone Deacetylase as a Means to Reverse Resistance to Angiogenesis Inhibitors: Phase I Study of Abexinostat Plus Pazopanib in Advanced Solid Tumor Malignancies Journal of Clinical Oncology 2017
Scientists discover gene that blocks spread of colon cancer MedicalXpress April 21, 2017
More information: Raphael Rapetti-Mauss et al. Bidirectional KCNQ1:β-catenin interaction drives colorectal cancer cell differentiation, Proceedings of the National Academy of Sciences (2017). DOI: 10.1073/pnas.1702913114
Oncodomains: A protein domain-centric framework for analyzing rare variants in tumor samples PLOS Computational Biology April 20, 2017
"Smart, new approach to analysis of rare somatic cancer variants" Eric Topol
Amino acids in diet could be key to starving cancer MedicalXpress April 19, 2017
Know the symptoms of oral cancer Mayo Clinic 4/17/2017
"Each year about 50,000 Americans are diagnosed with oral cancer; only one-half of them will be alive in five years."
"Close to Half of American Adults Infected With HPV" The New York Times APRIL 6, 2017 HPV causes nearly all cervical and oral cancers
Specialised blood vessels enhance tumour-fighting immunotherapy Drug Target Review 19 April 2017
"The successful combination of two therapies results in the growth of specialised vessels that deliver cancer-fighting immune cells to a tumour, potentially leading to more effective treatments and longer survival periods."
Nearly half of adults in US infected with HPV (human papillomavirus) MedicalXpress April 18, 2017
"HPV causes nearly all cervical and oral cancers"
Drug therapy: Exploiting synthetic lethality to improve cancer therapy Nature Reviews Clinical Oncology 29 March 2017
Synthetic lethality in lung cancer and translation to clinical therapies Mol Cancer. 2016; 15: 61
New test for early detection of lung cancer measures tiny changes in the composition of the breath MedicalXpress April 19, 2017
Non‐invasive lung cancer diagnosis by detection of GATA6 and NKX2‐1 isoforms in exhaled breath condensate EMBO Molecular Medicine (2016) 8, 1380-1389
Novartis advances with push on cancer and liver disease Reuters Health News Apr 18, 2017
"The Basel-based drugmaker's chimeric antigen receptor therapy (CAR-T) treatment, called CTL019, was awarded the U.S. Food and Drug Administration's breakthrough therapy designation for adults with relapsed/refractory (r/r) diffuse large B-cell lymphoma, a common blood cancer."
Personalized tumor vaccines keep cancer in check Science 14 Apr 2017
"An upbeat perspective on early individualized cancer vaccine expereince w/ multiple neoantigens" Eric Topol
Long-term Survival in Glioblastoma with Cytomegalovirus pp65-Targeted Vaccination Clinical Cancer Research April 2017
Conclusions: Despite increased Treg proportions following DI-TMZ, patients receiving pp65-DCs showed long-term PFS and OS, confirming prior studies targeting cytomegalovirus in glioblastoma. Clin Cancer Res; 23(8); 1898–909
Brain Cancer Vaccine–Chemotherapy Combo Shows Promise GEN News Highlights April 14, 2017
Associations Between Cancer Predisposition Testing Panel Genes and Breast Cancer Jama Oncology April 13, 2017
"Meaning Although pathogenic variants in several panel genes confer increased risks of breast cancer and may qualify patients for increased cancer surveillance, variants in several other cancer panel genes may not predispose to breast cancer."
"A multi-gene panel for breast cancer stirs a bit of controversy" Eric Topol
Can A Simple Blood Test Really Spot Cancer Early? Don’t Bet On It Yet, Scientists Say. BuzzFeedNews April 12, 2017
"Well-funded startups like Freenome and Grail say they’re making tests that spot cancer before you know you have it. They have divulged little about the science behind their vision — and many scientists are skeptical."
"Will the "liquid biopsy" blood test pan out for diagnosing cancer in healthy people?" Eric Topol
Oncologists await historic first: a pan-tumor predictive marker, for immunotherapy Nature Biotechnology 11 April 2017
"A predictive marker for cancer immunotherapy awaits US_FDA approval—but mismatch repair (MMR) ≠"pan-tumor" tag" Eric Topol
Researchers find novel way to induce pancreatic cancer cell death MedicalXpress April 10, 2017
""The potential therapeutic value of this finding is important because we could deliver MIR506 directly to pancreatic cancer cells using technologies like nanoparticles and exosomes," Zhang said."
'Synthetic biomarkers' could be used to diagnose ovarian cancer months earlier than now possible MedicalXpress April 10, 2017
More information: Ultrasensitive tumour-penetrating nanosensors of protease activity, Nature Biomedical Engineering, nature.com/articles/doi:10.1038/s41551-017-0054
Matching tumor size to strength of immune response allows melanoma drug tailoring MedicalXpress April 10, 2017
More information: T-cell reinvigoration adjusted for tumour burden is associated with anti-PD-1 response, Nature (2017). nature.com/articles/doi:10.1038/nature22079
"The size of tumor influences its response to #cancer immunotherapy w/ PD-1 blockade" Eric Topol
Newfound signal helps pancreatic cancer cells hide from immune system MedicalXpress April 10, 2017
More information: Dectin 1 activation on macrophages by galectin 9 promotes pancreatic carcinoma and peritumoral immune tolerance, Nature Medicine (2017). nature.com/articles/doi:10.1038/nm.4314
Fast capture of cancer markers will aid in diagnosis and treatment Phys Org April 10, 2017
More information: Rapid isolation of extracellular vesicles via lipid nanoprobes, Nature Biomedical Engineering (2017). nature.com/articles/doi:10.1038/s41551-017-0058
For every 1,000 men who get a PSA test every 1-4 years for a decade, 1 death from prostate cancer would be avoided. NCI Prevention
GEN List -- Top 10 Immuno-Oncology Collaborations GEN 2017 April 03, 2017
Metastasis - Breaching barriers Nature Reviews Cancer 07 April 2017
"Study shows cancer cells can survive and grow in cerebrospinal fluid by using a complement component."
PARP Inhibitors for Cancer Therapy Cell Volume 169, Issue 2, p183, 6 April 2017
"If you're into PARP inhibitors for cancer therapy, here are 2 new & useful publications" Eric Topol
Low-dose aspirin reduces risk for many cancers HemOnctoday April 6, 2017
"Adults who take low-dose aspirin over an extended period of time demonstrated lower mortality from many cancers, including breast cancer, prostate cancer and lung cancer, according to data presented at the American Association for Cancer Research Annual Meeting"
Cao, Y, et al. Abstract 3012. Presented at: AACR Annual Meeting; April 1-5, 2017; Washington, D.C.
Cancer-Causing HPV Virus Affects 25 Percent of U.S. Men: Study NBC News Apr 6 2017
Immunology Wars: Monoclonal Antibodies GEN Video Channel
"Our immune systems are at war with cancer. This animation from the journal Nature reveals how monoclonal antibodies can act as valuable reinforcements to shore up our defenses–and help battle cancer."
"Annual Report to the Nation 2017: Incidence Summary"
Targeted agents and immunotherapies: optimizing outcomes in melanoma Nature Reviews Clinical Oncology 04 April 2017
"the median overall survival of patients w/ advanced-stage melanoma increasing from approximately 9 months before 2011 to at least 2 years"
"Oncostatin M is a potential biomarker of & drug target for IBD, with particular relevance for anti-TNF-resistance:"
New drug delivery system shows promise for fighting solid tumors MedicalXpress April 4, 2017
"A new cancer-drug delivery system shows the ability to exploit the oxygen-poor areas of solid tumors that make the growths resistant to standard chemotherapy and radiation treatment."
See: Characterization of pegylated and non-pegylated liposomal formulation for the delivery of hypoxia activated vinblastine-N-oxide for the treatment of solid tumors Journal of Controlled Release Volume 253, 10 May 2017, Pages 37–45
New gene discovered drives cancer drug resistance Drug Target Review 4 April 2017
"Scientists in Salford, UK, have identified a gene which is ‘revving the engine of cancer’ against the world’s most common breast cancer drug.": the protein NQ01
Bristol-Myers immunotherapy combination extends survival in melanoma Reuters Apr 3, 2017
"Patients with advanced melanoma who received Bristol-Myers Squibb's immunotherapies Opdivo and Yervoy had improved overall survival compared with those on Yervoy alone, with 64 percent on the combination therapy still alive after two years, according to data released on Monday."
Telomere length predicts cancer risk MedicalXpress April 3, 2017
"The length of the telomere "caps" of DNA that protect the tips of chromosomes may predict cancer risk and be a potential target for future therapeutics, University of Pittsburgh Cancer Institute (UPCI) scientists will report today at the AACR Annual Meeting in Washington, D.C."
A 'sci-fi' cancer therapy fights brain tumors, study finds The Charlotte Observer April 3, 2017
"Study presented at AACR17 found that a wearable device improved survival for people with glioblastoma."
A 'sci-fi' cancer therapy fights brain tumors, study finds MedicalXpress April 2, 2017
The cost of cancer: new drugs show success at a steep price Reuters Apr 4, 2017
"Newer cancer drugs that enlist the body's immune system are improving the odds of survival, but competition between them is not reining in prices that can now top $250,000 a year." "The global market for cancer immunotherapies alone is expected to grow more than fourfold globally to $75.8 billion by 2022 from $16.9 billion in 2015, according to research firm GlobalData."
"Tobacco smoking is the most common cause of #lungcancer, but others include radiation and urban air pollution"
'Sniffing' urine to detect prostate cancer could prevent unnecessary biopsies MedicalXpress April 3, 2017
Patients' immune system may influence effectiveness of cancer immunotherapy MedicalXpress April 2, 2017
"Higher or lower levels of certain immune cells in cancer patients may be associated with how well they respond to immunotherapy, according to preliminary results of a study conducted by researchers at the University of Pittsburgh Cancer Institute (UPCI)."
Brain cancer survival improves with novel electrical device, data suggest The Washington Post April 2
"Brain cancer treated w/ electrical fields for $21,000/month?" Eric Topol
New molecules may offer treatment option for some aggressive prostate cancers MedicalXpress April 2, 2017
"Novel molecules called selective androgen receptor degraders (SARDs) may offer the next generation of treatment options for advanced prostate cancer, a new industry-sponsored study reports."
Prostate Cancer Screening — A Perspective on the Current State of the Evidence NEJM March 30, 2017
"How to help 1 in 1000 men and hurt hundreds... synthesis of routine PSA screening data" Eric Topol
Why Clovis' Advantage Might Squash Tesaro In Ovarian Cancer Investor's Business Daily 3/28/2017
Aspirin to Reduce Cancer Risk NCI 2017
"Aspirin may reduce the risk of colorectal cancer. Researchers are asking if the drug can help prevent other cancers"
Mark of malignancy identified in prostate cancer MedicalXpress March 31, 2017
"PSMA is already used as a target for delivering chemotherapy, but could be a good drug target itself. Because it seems to be activating pathways that make cells cancerous, shutting down PSMA might shut down a cancer."
More information: Leslie Ann Caromile et al. PSMA redirects cell survival signaling from the MAPK to the PI3K-AKT pathways to promote the progression of prostate cancer, Science Signaling (2017). DOI: 10.1126/scisignal.aag3326 - "PSMA is more than a diagnostic marker"
Scientists find surprising impact of junk DNA and RNA in cancer MedicalXpress March 31, 2017
More information: Lisa L. Hall et al. Demethylated HSATII DNA and HSATII RNA Foci Sequester PRC1 and MeCP2 into Cancer-Specific Nuclear Bodies, Cell Reports (2017). DOI: 10.1016/j.celrep.2017.02.072
"We learned a lot about the genomics of brain cancer this wk" Eric Topol
Team creates triple-threat cancer-fighting polymer capsules for guided drug delivery Phys Org March 30, 2017
More information: Jun Chen et al, Theranostic Multilayer Capsules for Ultrasound Imaging and Guided Drug Delivery, ACS Nano (2017). DOI: 10.1021/acsnano.7b00151
"Therapeutic levels of vitamin C sensitize non-small-cell lung cancer & glioblastoma to conventional therapies"
Cruel fusion: What a young man’s death means for childhood cancer - Epigenetic discoveries are fuelling renewed interest in the fusion proteins that have bedevilled cancer biologists. Nature 05 April 2017
"For cancer, we're learning about the interaction of fusion proteins and epigenetics" Eric Topol
Cancer: Tumour stem-cell surprises Nature Niews and Views 30 March 2017
"Stem-cell divisions are thought to be essential to tumour growth. Targeted removal of a specific stem-cell population reveals its role in tumour development and in the growth of tumours formed by cell migration to distant sites."
"Demonstrating the pivotal importance of stem cells in cancer" Eric Topol
See: A distinct role for Lgr5+ stem cells in primary and metastatic colon cancer Nature 29 March 2017
"Together, our data highlight distinct CSC dependencies for primary versus metastasic tumour growth, and suggest that targeting CSCs may represent a therapeutic opportunity for managing metastatic disease."
Novartis wins speedy U.S. review of new leukemia drug Reuters Mar 30, 2017
"The FDA's announcement late Wednesday means the regulator plans to take action within six months on Novartis's so-called chimeric antigen receptor T cell therapy, or CAR-T, in partnership with University of Pennsylvania researchers."
1 in 14 Men & 1 in 17 Women will develop LungCancer. Know the facts free to breathe 2017
The cancer immunity cycle Roche 2017
"The cancer immunity cycle developed by Dan Chen and Ira Mellman has become the intellectual framework for cancer immunotherapy research. See below for a slideshow that explains each step of the cycle."
"The process by which the immune system kills cancer cells is described by the cancer-immunity cycle."
Gene research gives new insight into pancreatic cancer MedicalXpress March 29, 2017
More information: N L E Harris et al. SerpinB2 regulates stromal remodelling and local invasion in pancreatic cancer, Oncogene (2017). DOI: 10.1038/onc.2017.63
Designing a Novel Cancer Drug: From Hit ID to Candidate Webminar Drug Target Review Charles River Laboratory 14 March 2017
Functional variomics and network perturbation: connecting genotype to phenotype in cancer Nature Reviews Genetics 27 March 2017
"The multitude of mutations in cancer, but which ones are functional? a stellar review" Eric Topol
FDA approves Tesaro's ovarian cancer drug Reuters Mar 28, 2017
Stem cell divisions, somatic mutations, cancer etiology, and cancer prevention Science 24 Mar 2017
Cancer and the unavoidable R factor
"Most textbooks attribute cancer-causing mutations to two major sources: inherited and environmental factors. A recent study highlighted the prominent role in cancer of replicative (R) mutations that arise from a third source: unavoidable errors associated with DNA replication. Tomasetti et al. developed a method for determining the proportions of cancer-causing mutations that result from inherited, environmental, and replicative factors (see the Perspective by Nowak and Waclaw). They found that a substantial fraction of cancer driver gene mutations are indeed due to replicative factors. The results are consistent with epidemiological estimates of the fraction of preventable cancers."
"The controversial "bad luck" cancer story, revisited...now w/ data to reinforce importance of DNA replication errors" Eric Topol
Profiling protein expression in circulating tumour cells using microfluidic western blotting Nature Communications 2017
"The seemingly limitness information about an individual's cancer from a tube of blood a 1 cell level" Eric Topol
Is there a link between telomere length and cancer? MedicalXpress March 23, 2017
More information: Philip C. Haycock et al. Association Between Telomere Length and Risk of Cancer and Non-Neoplastic Diseases, JAMA Oncology (2017). DOI: 10.1001/jamaoncol.2016.5945
Non-invasive prostate cancer diagnosing, monitoring Phys Org March 22, 2017
More information: Parissa Ziaei et al, Silica nanostructured platform for affinity capture of tumor-derived exosomes, Journal of Materials Science (2017). DOI: 10.1007/s10853-017-0905-0
How the nervous system controls tumor growth MedicalXpress March 22, 2017
More information: Benoni Boilly et al. Nerve Dependence: From Regeneration to Cancer, Cancer Cell (2017). DOI: 10.1016/j.ccell.2017.02.005
Immunotherapy - Genomic and immunological features predict a response Nature Reviews Clinical Oncology 2017
"When self-reporting by patients helps future patient choices: key data for men w/ dx ProstateCancer" Eric Topol
Novel genes identified that help suppress prostate and other cancers Drug Target Review 20 March 2017
Popular Prostate Cancer Therapy Is Short, Intense and Unproven The New York Times MARCH 20, 2017
"Are 5 intense radiation treatments over 2 weeks to treat prostate cancer better than 40 over 2 months? No one knows."
Immunotherapy- Start your engineering — CARs take to the TRAC Nature Reviews Clinical Oncology 2017
Synergistic drug combinations for cancer identified in a CRISPR screen for pairwise genetic interactions Nature Biotechnology 2017
When less is more Science 17 Mar 2017
"For decades, cancer treatments have been given to patients continually at the maximum dose that can be tolerated. But a few labs are challenging that dogma. They are motivated by theoretical models of cancer growth and evidence from animal studies suggesting that briefly stopping or cutting back a drug dose can help keep the cancer cells from becoming resistant to the drug and can even trigger some cells to die, extending patients' lives...."
""Timing is everything" - that adage may to less, timed cancer therapy, too"" Eric Topol
Drugging RAS: Know the enemy Science 17 Mar 2017
"How to take on RAS mutations, a key driver in cancer, yet unsolved" Eric Topol
Waste disposal—An attractive strategy for cancer therapy Science 17 Mar 2017
"We first discuss examples of existing cancer drugs that work by degrading specific proteins and then review recent progress in the rational design and preclinical testing of small molecules that induce selective degradation of specific target proteins."
"Getting rid of the waste for cancer therapy, a workround plane for undruggable targets" Eric Topol
Strategies and challenges for the next generation of antibody–drug conjugates for cancer therapy Nature Reviews Drug Discovery 17 March 2017
Microbiota: a key orchestrator of cancer therapy Nature Reviews Cancer 17 March 2017
The cancer epigenome: Concepts, challenges, and therapeutic opportunities Science 17 Mar 2017
"The cancer epigenome: a 1st rate review" Eric Topol
"2 papers show that therapeutic effect of PD-1 blockade occurs via targeting of CD28":
Rescue of exhausted CD8 T cells by PD-1–targeted therapies is CD28-dependent Science 09 Mar 2017
T cell costimulatory receptor CD28 is a primary target for PD-1–mediated inhibition Science 09 Mar 2017
Researchers explore a potential therapeutic approach against cancer stem cells MedicalXpress March 15, 2017
More information: Pre-clinical validation of a selective anti-cancer stem cell therapy for Numb-deficient human breast cancers, DOI: 10.15252/emmm.201606940
The high price of anticancer drugs: origins, implications, barriers, solutions Nature Reviews Clinical Oncology 14 March 2017
Degrons in cancer Sci. Signal. 14 Mar 2017
"What are degrons? Everything you wanted to know but were afraid to ask here for their role in cancer" Eric Topol
Colorectal cancer - Screening provides long-term benefits Nature Reviews Clinical Oncology 14 March 2017
FDA approves CDK4/6 inhibitor ribociclib for treatment of breast cancer: Ribociclib (Kisqali) U.S. Food and Drug Administration Last Updated: 03/14/2017
Review: The history and future of targeting cyclin-dependent kinases in cancer therapy NATURE REVIEWS - DRUG DISCOVERY 2015
Gene mutation found to drive prostate cancer subtype MedicalXpress March 14, 2017
More information: www.cell.com/cancer-cell/fulltext/S1535-6108(17)30047-8
Non-kinase targets of protein kinase inhibitors Nature Reviews Drug Discovery 10 March 2017
Researcher finds mechanism triggering spread of prostate cancer to bones MedicalXpress March 13, 2017
More information: Cancer Cell, DOI: 10.1016/j.ccell.2017.02.003
Benzene formation in electronic cigarettes PLOS March 8, 2017
Cancer-causing benzene found in e-cigarette vapors operated at high power ScienceDaily March 8, 2017
Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia The IRIS Trial NEJM 2017
"Chronic myeloid leukemia, a myeloproliferative neoplasm, is associated with the Philadelphia chromosome. Imatinib targets the product of the chromosome, but little has been known about long-term safety and efficacy. New research findings are summarized in a short video."
Cancer Pill Gleevec Keeps Patients Alive and Well for a Decade NBC NEWS Mar 9 2017
Neuroscientists pinpoint key gene controlling tumor growth in brain cancers MedicalXpress March 9, 2017
More information: Lincoln A. Edwards et al, ZEB1 regulates glioma stemness through LIF repression, Scientific Reports (2017). DOI: 10.1038/s41598-017-00106-x
"Accumulating evidence shows that there are simple methods of reducing the incidence of cancer and cancer-related mortality in people at average and high risk. Further study is needed to better understand how these lifesaving, cost-effective measures can be put to greater use."
"To prevent cancer, we need better implementation science "our moonshot is here, ready for the taking"" Eric Topol
Vitamin C effective at targeting cancer stem cells Drug Target Review 9 March 2017
"Vitamin C is up to ten times more effective at stopping cancer cell growth than pharmaceuticals such as 2-DG, according to an article published in Oncotarget"
Pivotal Year Looms for CAR T-Cell Therapies OncLive March 01, 2017
Male breast cancer discovery could improve treatment MedicalXpress March 8, 2017
"Two key proteins involved in male breast cancer have been identified by University of Leeds scientists, potentially paving the way for more effective treatments."
More information: Matthew P. Humphries et al, A Case-Matched Gender Comparison Transcriptomic Screen Identifies eIF4E and eIF5 as Potential Prognostic Markers in Male Breast Cancer, Clinical Cancer Research (2016). DOI: 10.1158/1078-0432.CCR-16-1952
Breakthrough discovery may make blood test feasible for detecting cancer MedicalXpress March 8, 2017
"Tao and his colleagues found nearly 2,400 phosphoproteins in a blood sample and identified 144 that were significantly elevated in cancer patients."
More information: I-Hsuan Chen et al. Phosphoproteins in extracellular vesicles as candidate markers for breast cancer, Proceedings of the National Academy of Sciences (2017). DOI: 10.1073/pnas.1618088114
DNA Motors in Living Cells Start with MicroRNA Keys GEN News Highlights March 7, 2017
"DNA motors built by scientists have been running smoothly inside cancer cells"
OncoCyte says study confirms accuracy of lung cancer blood test Reuters Mon Mar 6, 2017
Team Describes Novel High-Throughput Cancer Screening System GEN News Highlights March 1, 2017
Integrating liquid biopsies into the management of cancer Nature Reviews Clinical Oncology 02 March 2017
Roche trial finds new drug cocktail cuts breast cancer deaths Reuters Thu Mar 2, 2017
"Combining its drug Perjeta with Herceptin and chemotherapy after surgery cut recurrence of an aggressive type of early breast cancer or death compared to Herceptin and chemo, the Swiss pharmaceuticals giant said in a statement on Thursday."
Newly discovered vulnerability in an aggressive breast cancer provides therapeutic target MedicalXpress March 2, 2017
More information: Adaptive Reprogramming of De Novo Pyrimidine Synthesis Is a Metabolic Vulnerability in Triple-Negative Breast Cancer, DOI: 10.1158/2159-8290.CD-16-0611 , cancerdiscovery.aacrjournals.org/content/early/2017/02/28/2159-8290.CD-16-0611
Shorter herceptin breast cancer treatment may produce better results MedicalXpress March 1, 2017
Breast cancer patients who receive the drug Herceptin for nine weeks as part of their post-surgery chemotherapy regime may enjoy better health outcomes, according to new research led by UCL, compared to those who receive it for 12 months, the period currently recommended in the English NHS."
Absent tumor-suppressors allow melanoma to thwart immunotherapy MedicalXpress March 1, 2017
More information: "Integrated molecular analysis of tumor biopsies on sequential CTLA-4 and PD-1 blockade reveals markers of response and resistance," Science Translational Medicine, stm.sciencemag.org/lookup/doi/10.1126/scitranslmed.aah3560
Kite Pharma Reports Positive 6-Month Trial Data for Lead CAR-T Candidate GEN News Highlights February 28, 2017
Kite's shares fly high after cancer drug clears main study goal Reuters Tue Feb 28, 2017
Genetic 'balance' may influence response to cancer treatment MedicalXpress February 28, 2017
More information: Michael R. Burgess et al. KRAS Allelic Imbalance Enhances Fitness and Modulates MAP Kinase Dependence in Cancer, Cell (2017). DOI: 10.1016/j.cell.2017.01.020
Scientists uncover molecule that can destroy cancer tumour cells whilst leaving normal cells unaffected MedicalXpress February 27, 2017
More information: C J Dunnill et al. A redox state-dictated signalling pathway deciphers the malignant cell specificity of CD40-mediated apoptosis, Oncogene (2016). DOI: 10.1038/onc.2016.401
Scientists identify chain reaction that shields breast cancer stem cells from chemotherapy MedicalXpress February 22, 2017
More information: Haiquan Lu et al. Chemotherapy-Induced Ca2+ Release Stimulates Breast Cancer Stem Cell Enrichment, Cell Reports (2017). DOI: 10.1016/j.celrep.2017.02.001
Response to Cancer Immunotherapy May Depend on Gut Bacteria ASCO February 21, 2017
“Immunotherapy is rapidly improving the lives of people with cancer, but it doesn’t work for many patients, and we still don’t know why,” said ASCO Expert Lynn Schuchter, MD, FASCO. “These results open the door for new approaches to boosting patients’ responses to PD-1 drugs, potentially by tinkering with the composition of gut bacteria.”
Association Between Telomere Length and Risk of Cancer and Non-Neoplastic DiseasesA Mendelian Randomization Study JAMA Oncology February 23, 2017
"So you think you want long telomeres? Not so fast...association w/ risk of #cancer… refutes a recent book" Eric Topol
The road to precision oncology Nature Genetics 24 February 2017
"Knowledge banks and the road to precision oncology" Eric Topol
Targeting neoantigens to augment antitumour immunity Nature Reviews Cancer 24 February 2017
ALKBH7 Variant Related to Prostate Cancer Exhibits Altered Substrate Binding PLOS Computational Biology February 23, 2017
"We've known prostate cancer is more common among African Americans A novel mutation reported" Eric Topol
Soon we'll be able to spot diseases like cancer before we even feel sick - "Within five years nanotechnology will examine bodily fluids for tiny bioparticles that reveal signs of cancer – helping to stop disease before it progresses" The Guardian 15 February 2017
Alecensa provides an efficacious, systemic treatment option for people with ALK-positive NSCLC, which is also active in patients with brain metastases, who have been previously treated with crizotinib
Countering the genome reprogramming of cancer cells Novartis Jan 30, 2017
"Novel PRC2 inhibitor changes the expression of hundreds of genes in cancer cells" - "Chemical biology screen uncovers PRC2 inhibitor via EED" Robert Plenge
Direct evidence for cancer-cell-autonomous extracellular protein catabolism in pancreatic tumors Nature Medecine FEBRUARY 2017
"A new study suggests that #cancer cells incorporate proteins in their microenvironment as a source of amino acids"
Approvals in 2016: questioning the clinical benefit of anticancer therapies Nature Reviews Clinical Oncology 20 February 2017
"Booth & Del Paggio now live: only 1 of 10 evaluated approved agents led to meaningful clinical benefit for patients"
The Antigenicity of the Tumor Cell — Context Matters NEJM February 2, 2017
"When is a neoantigen not a neoantigen? A recent study suggests that T cells in a patient with cancer are more likely to “miss” mutant peptides generated by somatic mutations than are the T cells in a healthy person."
Expanding the Cancer Arsenal with Targeted Therapies: Disarmament of the Antiapoptotic Bcl-2 Proteins by Small Molecules J. Med. Chem. 2017, 60 (3), pp 821–838
A New Model for Defeating Cancer: CAR T Cells Scientific American March 2017
Some advanced cancers can now be successfully treated by synthetic immune cells that are more powerful and longer-lasting than any found in the body
"Engineering T cells for #cancer immunotherapy nice graphic by..." Eric Topol
Putting data in the hands of doctors MIT February 16, 2017
"MIT Professor Regina Barzilay has struck up new research collaborations, drawn in MIT students, launched projects with local doctors, and begun empowering cancer treatment with the machine-learning insight that has already transformed many areas of modern life."
"Computer scientist Regina Barzilay empowers cancer treatment with machine learning."
Osimertinib in EGFR T790M–Positive Lung Cancer NEJM Resident 360 Feb 15, 2017
"Clinical Pearls & Morning Reports: Osimertinib in EGFR T790M–Positive Lung Cancer"
The Future of Glioblastoma OncLive Feb 15, 2017
From basic apoptosis discoveries to advanced selective BCL-2 family inhibitors Nature Reviews Drug Discovery Nature Reviews Drug Discovery
"Here we review the latest progress in direct and selective targeting of BCL-2 family proteins for cancer therapy."
Role of rogue protein PAK4 confirmed in pancreatic cancer cells MedicalXpress February 17, 2017
More information: Helen King et al, PAK4 interacts with p85 alpha: implications for pancreatic cancer cell migration, Scientific Reports (2017). DOI: 10.1038/srep42575
Liquid Biopsies, What We Do Not Know (Yet) Cancer Cell 13 February 2017 & Next-Generation Sequencing of Circulating Tumor DNA for Early Cancer Detection Cell 9 February 2017
"The future & the unknowns of liquid biopsy for cancer" Eric Topol
The double edge of cancer immunotherapy Nature Medicine 07 February 2017
"A succinct summary on the status and unknowns of cancer immunotherapy" Eric Topol
With colon cancer, smokers may be less likely to survive Reuters Wed Feb 15, 2017
"New study identifies Aurora Kinase A as a therapeutic target in lungcancer with mutant SMARCA4 CTD2"
Novel Technique Developed to Attack Solid Tumors GEN News Highlights February 14, 2017
"161 trial of CAR T cells for cancer worldwide, 0 trials of gene-modified T cells for HIV" The Lancet HIV
Treating Cancer without Harming the Heart NCI Posted: December 7, 2015
Characterization of Human Cancer Cell Lines by Reverse-phase Protein Arrays Cancer Cell 13 February 2017
"RPPA-based markers are predictors of drug sensitivity in human cancer cell lines & a portal for exploring data"
"Using reverse-phase protein arrays, we measured expression levels of ∼230 key cancer-related proteins in >650 independent cell lines,"
‘Did He Who Made the Lamb Make Thee?’ New Developments in Treating the ‘Fearful Symmetry’ of Acute Myeloid Leukemia Trends in Molecular Medecine February 2017
Silke & co review cell death pathways in the development & treatment of AML
Contribution of epigenetic mechanisms to variation in cancer risk among tissues PNAS January 21, 2017
"Tissue-specific epigenetics and the risk of cancer (an aberrant age-dependent methylation story)" Eric Topol
Taking a high-priced cancer drug with a low-fat meal can cut cost by 75 percent MedicalXpress February 13, 2017
Study revealed a new way to kill cancer cells DailyTalk in September 17, 2016
"Scientists at Harvard Medical School have discovered how certain tumors build up a preference for fat over sugar and that restricted to slaughter them could keep them from their life-managing fuel. The discoveries demonstrated how an instrument that regularly holds fat copying under wraps goes astray in a few malignancies, revving up fat utilization and fuelling tumor development."
More Fat, Please. Cancers' taste for fat may prove to be their Achilles' heel HarvardMedecine Magazine Autumn 2016
Notch as a tumour suppressor Nature Reviews Cancer 03 February 2017
"How does Notch function as a tumour suppressor? New Review:"
Common Cancer Myths and Misconceptions NCI Posted: February 3, 2014
"cancer cells consume more sugar than normal cells, but no studies show that eating sugar will make cancer worse"
What Is CRISPR? How can CRISPR be used to treat cancer? CancerToday
Emerging Biological Principles of Metastasis Cell Volume 168, Issue 4, p670–691, 9 February 2017
"In this review we summarize the cellular and molecular mechanisms involved in metastasis, with a focus on carcinomas where the most is known, and we highlight the general principles of metastasis that have begun to emerge."
Dozens Of New Cancer Drugs Do Little To Improve Survival, Frustrating Patients KHN February 9, 2017
Overall cancer survival has barely changed over the past decade. The 72 cancer therapies approved from 2002 to 2014 gave patients only 2.1 more months of life "than older drugs, according to a study in JAMA Otolaryngology–Head & Neck Surgery."
Clinical Benefit, Price and Approval Characteristics of FDA-approved New Drugs for Treating Advanced Solid Cancer, 2000-2015 Annals of Oncology
08 February 2017
A Look Ahead Cancer Immunotherapy Breakthroughs on the Horizon, with Jedd D. Wolchok Cancer Research Institute YouTube 24 janv. 2017
Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy Cell Volume 168, Issue 4, p707–723, 9 February 2017
Scientists can predict in the lab whether a drug will be effective for individual colorectal tumours MedicalXpress February 10, 2017
More information: Moritz Schütte et al. Molecular dissection of colorectal cancer in pre-clinical models identifies biomarkers predicting sensitivity to EGFR inhibitors, Nature Communications (2017). DOI: 10.1038/ncomms14262
How Much Longer Will We Put Up With $100,000 Cancer Drugs? Cell Volume 168, Issue 4, p579–583, 9 February 2017
Enzyme that regulates DNA repair may offer new precision treatments for breast and ovarian cancer Mayo Clinic December 12, 2016
Extrachromosomal oncogene amplification drives tumour evolution and genetic heterogeneity Nature 08 February 2017
"Here we show that ecDNA was found in nearly half of human cancers; its frequency varied by tumour type, but it was almost never found in normal cells. Driver oncogenes were amplified most commonly in ecDNA, thereby increasing transcript level."
Cancer genes hide outside chromosomes The San Diego Union-Tribune Feb 8, 2017
"Paul Mischel and his team recently learned Oncogenes, genes with cancer-promoting variations, aren't always on chromosomes, where scientists normally search for them. The Oncogenes, which drive cancer's ability to develop drug resistance, sometimes live on circular pieces of extrachromosomal DNA that are usually overlooked."
Academics call time on $100,000 cancer drugs Reuters Thu Feb 9, 2017
"A group of academic researchers has demanded an end to cancer medicines costing more than $100,000 a year and proposed a new model of low-cost drug development that would capitalise on recent advances in science."
The problem with neoantigen prediction Nature Biotechnology 2017
"Personalized immunotherapy is all the rage, but neoantigen discovery and validation remains a daunting problem."
The double edge of cancer immunotherapy Nature Medicine 2017
"Immune-related adverse effects are understudied and not easily treatable risks of cancer immunotherapy. Concerted research efforts to understand the mechanisms of immunotherapy-triggered responses are crucial for developing better treatments."
Scientists turn food poisoning microbe into powerful cancer fighter Science Feb. 8, 2017
"Now, scientists have modified Salmonella bacteria to trigger a particularly powerful immune response against human cancer cells implanted in mice, shrinking the tumors and—for the first time—preventing them from metastasizing. If the technique can be replicated in humans, it would be a significant step forward for the field of bacterial cancer therapy."
Two-step enhanced cancer immunotherapy with engineered Salmonella typhimurium secreting heterologous flagellin Science Translational Medicine 08 Feb 2017
Study reveals how melanoma spreads MedicalXpress February 8, 2017
More information: Stacie K. Loftus et al. Hypoxia-induced HIF1targets in melanocytes reveal a molecular profile associated with poor melanoma prognosis, Pigment Cell & Melanoma Research (2017). DOI: 10.1111/pcmr.12579
An alternative theory on how aspirin may thwart cancer MedicalXpress February 8, 2017
More information: Lenard M. Lichtenberger et al. Unlocking Aspirin's Chemopreventive Activity: Role of Irreversibly Inhibiting Platelet Cyclooxygenase-1, Cancer Prevention Research (2017). DOI: 10.1158/1940-6207.CAPR-16-0241
"In this study, using colon cancer as an example, we provide both in vitro (cell culture) and in vivo (chemically induced mouse model of colon cancer) evidence that this profound antineoplastic action may be associated with aspirin's ability to irreversibly inhibit COX-1–mediated platelet activation, thereby blocking platelet–cancer cell interactions, which promote cancer cell number and invasive potential."
Marcus Krause's lung cancer wouldn't stop growing. Then he took a new kind of blood test WIRED 5 February 2017
"Guardant Health's blood test monitors a tumour's DNA and could offer a whole new approach to saving lives"
Immunotherapy Shows Promise Against Previously Untreatable Stomach Cancer Cancer Research Institute January 23, 2017
Genetic Testing and Counseling Among Patients With Newly Diagnosed Breast Cancer JAMA February 7, 2017
Study of cancer-causing toxins finds e-cigarettes much safer than smoking Reuters Mon Feb 6, 2017
""Our study adds to existing evidence showing that e-cigarettes and NRT are far safer than smoking, and suggests that there is a very low risk associated with their long-term use," said Lion Shahab, a specialist in epidemiology and public health at University College London who led the work."
E-cigarettes safer than smoking says long-term study Cancer Research UK 6 February 2017
Use of Nivolumab Expanded to Sixth Cancer Type February 6, 2017
"Nivolumab works by releasing a brake (or checkpoint protein) called PD-1 on cancer-fighting immune cells called T cells. Nivolumab releases the PD-1 brake by preventing it from being engaged by two proteins called PD-L1 and PD-L2. Once the PD-1 brake is released by nivolumab, the T cells are able to destroy cancer cells."
Nanoplasmonic quantification of tumour-derived extracellular vesicles in plasma microsamples for diagnosis and treatment monitoring Nature Biomedical Engineering 2017
"New dimension of liquid biopsy for cancer - extracellular vesicles" Eric Topol
Immune system genes linked to most common type of leukaemia MedicalXpress February 6, 2017
""CLL is essentially a disease of the immune system, and it's fascinating that so many of the new genetic variants we have uncovered seem to directly affect the behaviour of white blood cells and their ability to fight disease."
Teens use e-cigarettes for 'dripping,' study says CNN February 7, 2017
"One in four teens who vape say they've used e-cigarettes for an alternative technique known as "dripping," new research finds."
ECCO 2017: Melanoma Death Rates Will Fall by 2050, but Number of Deaths Will Increase The ASCO Post 2/2/2017
The experimental gene therapy treatment that helped one woman fight cancer TODAY Health and Wellness Feb. 6, 2017
Lung cancer survival only increases by a small amount despite recent treatment advances The Lancet Respiratory Medecine 03 February 2017
"Median overall survival among patients with advanced non-small-cell lung cancer (NSCLC) in the USA has increased by only 1·5 months in more than a decade despite the advent of several new antineoplastic drugs, according to new research published in the Journal of Clinical Oncology."
Researchers identify 'synthetic essentiality' as novel approach for locating cancer therapy targets MedicalXpress February 6, 2017
More information: Synthetic essentiality of chromatin remodeling factor CHD1 in PTEN-deficient cancer, Nature, nature.com/articles/doi:10.1038/nature21357
"Conclusion This study contributes to the growing evidence that psychological distress might have some predictive capacity for selected cancer presentations, in addition to other somatic diseases."
"One recent 1st rate paper on stress and disease" Eric Topol
Precision oncology for acute myeloid leukemia using a knowledge bank approach Nature Genetics 16 January 2017
CIViC is a community knowledgebase for expert crowdsourcing the clinical interpretation of variants in cancer Nature Genetics 31 January 2017
"Knowledge banks, a big part of medecine's future: 1st 2 are for cancer" Eric Topol
DNA methylation heterogeneity defines a disease spectrum in Ewing sarcoma Nature Medicine 30 January 2017
"So much attention has been paid to tumor genomic heterogeneity; but epigenomic variation is important, too" Eric Topol
U.S. FDA approves Bristol-Myers' Opdivo for bladder cancer Reuters Thu Feb 2, 2017
Human-Machine Collaboration in Cancer and Beyond JAMA Oncol. February 2, 2017
"Human-machine in cancer care" Eric Topol
Brain Cancer Treatment Puts Skin in the Game GEN News Highlights Feb 2, 2017
"Neural stem cells (NSCs) are ideal recruits for search-and-destroy missions in the brain. They have an innate ability to home in on cancer cells, and they can be engineered to release therapeutic agents. However, they can be hard to obtain from patients. And if they are called up from donors, NSCs bring the risk of adverse immune reactions and other complications. A safer alternative is to put some skin in the game—the patient’s own skin, that is. Human skin cells can be reprogrammed to become NSCs."
Experts Forecast Cancer Research and Treatment Advances in 2017 AACR January 6, 2017
New technology to speed up testing of cancer drugs MedicalXpress January 31, 2017
More information: Delyan P. Ivanov et al. Spheroid arrays for high-throughput single-cell analysis of spatial patterns and biomarker expression in 3D, Scientific Reports (2017). DOI: 10.1038/srep41160
Countering the genome reprogramming of cancer cells Novartis Jan 30, 2017
"Novel PRC2 inhibitor changes the expression of hundreds of genes in lab model"
"The compound showed promise in a mouse model of B-cell lymphoma, changing the expression of hundreds of genes and inducing tumor regression, a discovery reported in Nature Chemical Biology (An allosteric PRC2 inhibitor targeting the H3K27me3 binding pocket of EED). Safety and efficacy remain to be proven in humans."
Clue to how cancer cells spread Yale January 27, 2017
"A melanoma cancer cell and white blood cell can fuse together to become metastatic"
Two Infants Treated with Universal Immune Cells Have Their Cancer Vanish MIT Technology Review January 25, 2017
See Molecular remission of infant B-ALL after infusion of universal TALEN gene-edited CAR T cells Science Translational Medicine 25 Jan 2017
Unraveling the mystery of why cancer cells survive and thrive MedicalXpress January 30, 2017
""These cancer cells are hijacking a mechanism to maintain telomeres, enabling them to continue to divide," Verhaak says."
More information: Systematic analysis of telomere length and somatic alterations in 31 cancer types, Nature Genetics, nature.com/articles/doi:10.1038/ng.3781
Magnesium silicide nanoparticles as a deoxygenation agent for cancer starvation therapy Nature Nanotechnology 09 January 2017
Reporter gene imaging of targeted T cell immunotherapy in recurrent glioma Science Translational Medicine 18 Jan 2017
Treatment-associated toxicities reported by patients with early-stage invasive breast cancer Cancer 24 January 2017
MicroRNA-141 suppresses prostate cancer stem cells and metastasis by targeting a cohort of pro-metastasis genes Nature Communications 23 January 2017
The recurrent architecture of tumour initiation, progression and drug sensitivity Nature Reviews Cancer 2017
"How can we identify the master regulator proteins of cancer?"
Cancer cell motility: lessons from migration in confined spaces Nature Reviews Cancer 2017
Prostate Cancer and Prostatic Diseases 2017
"Conclusions: Non-rising PSA at radiographic progression is a common phenomenon in mCRPC patients treated with enzalutamide. As restaging in advanced prostate cancer patients is often guided by increases in PSA levels, our results demonstrate that disease progression on enzalutamide can occur without rising PSA levels. Therefore, a disease monitoring strategy that includes imaging not entirely reliant on serial serum PSA measurement may more accurately identify disease progression."
A Validated Multiscale In-Silico Model for Mechano-sensitive Tumour Angiogenesis and Growth PLOS Computational Biology 2017
"As the tumor grows...the nutient blood suply can be compressed-3D modelling" Eric Topol
Could Opdivo worries turn BMS into an M&A target? One analyst thinks so FiercePharma Jan 26, 2017
Two leukemia babies in remission after injection of new kind of edited T-cells MedicalXpress January 26, 2017
"Two babies given an experimental kind of edited T-cells to treat their leukemia remain in remission after more than a year, doctors working on the case report in a paper published in the journal Science Translational Medicine. The research team is affiliated with several institutions in the U.K."
More information: Waseem Qasim et al. Molecular remission of infant B-ALL after infusion of universal TALEN gene-edited CAR T cells, Science Translational Medicine (2017). DOI: 10.1126/scitranslmed.aaj2013
Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial The Lancet 2017
Immunotherapy Shows Promise Against Previously Untreatable Stomach Cancer Cancer Research Institute January 23, 2017
Better understanding of how prostate cancer spreads around the body MedicalXpress January 25, 2017
More information: Naomi Harner-Foreman et al. A novel spontaneous model of epithelial-mesenchymal transition (EMT) using a primary prostate cancer derived cell line demonstrating distinct stem-like characteristics, Scientific Reports (2017). DOI: 10.1038/srep40633
Predicting and preventing prostate cancer spread MedicalXpress January 25, 2017
More information: Rajdeep Das et al. MicroRNA-194 promotes prostate cancer metastasis by inhibiting SOCS2, Cancer Research (2016). DOI: 10.1158/0008-5472.CAN-16-2529
Research team identifies role for a microRNA involved in prostate cancer metastasis MedicalXpress January 25, 2017
More information: Can Liu et al. MicroRNA-141 suppresses prostate cancer stem cells and metastasis by targeting a cohort of pro-metastasis genes, Nature Communications (2017). DOI: 10.1038/ncomms14270
Proteasome inhibitors in cancer therapy Nature Reviews Clinical Oncology 2017
On target: Researchers arm platelets to deliver cancer immunotherapy MedicalXpress January 23, 2017 2017
More information: Chao Wang et al, In situ activation of platelets with checkpoint inhibitors for post-surgical cancer immunotherapy, Nature Biomedical Engineering (2017). DOI: 10.1038/s41551-016-0011
New biomarker allows better prediction of survival for patients with colorectal metastases MedicalXpress January 23, 2017
More information: S. Stremitzer et al. Expression of Genes Involved in Vascular Morphogenesis and Maturation Predicts Efficacy of Bevacizumab-Based Chemotherapy in Patients Undergoing Liver Resection, Molecular Cancer Therapeutics (2016). DOI: 10.1158/1535-7163.MCT-16-0275
Reporter gene imaging of targeted T cell immunotherapy in recurrent glioma Science Translational Medecine 2017
"Imaging immunotherapy in action for brain cancer" Eric Topol
Study shows that nanoparticles serve as a good tumor deoxygenation agent Phys Org January 20, 2017
More information: Chen Zhang et al. Magnesium silicide nanoparticles as a deoxygenation agent for cancer starvation therapy, Nature Nanotechnology (2017). DOI: 10.1038/nnano.2016.280
Study Finds New Way to Pinpoint Dangerous Prostate Cancer NBC NEWS Jan 12 2017
"The main determinant of whether the men would die, the team found, was how low their PSA level fell. If it did not drop to 0.5 after treatment, the men were most likely to have the cancer come back and kill them, D'Amico said."
Surrogate End Points for All-Cause Mortality in Men With Localized Unfavorable-Risk Prostate Cancer Treated With Radiation Therapy vs Radiation Therapy Plus Androgen Deprivation TherapyA Secondary Analysis of a Randomized Clinical Trial JAMA ONCOLOGY January 12, 2017
Vitamin C could treat cancer: High dose of substance found in LEMONS kills deadly cells SUNDAY EXPRESS Jan 11, 2017
State Cancer Profiles NCI 2017
Case Report of Regression of Glioblastoma After Chimeric Antigen Receptor T-Cell Therapy The ASCO POST 1/12/2017
Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell Therapy NEJM December 29, 2016
Analyst says Celyad takes lead in CAR-T for solid tumors as THINK trial gets underway FierceBiotech Jan 13, 2017
"Could Aurora kinase inhibition combined with chemotherapy be an effective treatment approach for MYC+ SCLC?" NatureRevClinOncol
Study suggests small cell lung cancer should not be treated as single disease Cancer Research UK 13 January 2017
"We urgently need new drugs for this hard to treat cancer,” said Dr Alastair Greystoke
Vivre Avec un Cancer du Poumon un site pour accompagner les patients AstraZeneca 2017
Germline BRCA2 mutations drive prostate cancers with distinct evolutionary trajectories Nature Communications 2017
"New insights on the genetic landscape of localized prostate cancer" NatureRevClinOncol
Expert Discusses Docetaxel's Continued Significance in Prostate Cancer OncLive Jan 11, 2017
"Despite advances in targeted therapy and immunotherapy, chemo retains a key role in advanced prostate cancer"
Vertex deals cancer drug programs to Merck KGaA for $230M Boston Business Journal Jan 11, 2017
Research holds promise for personalized lung cancer treatments MedicalXpress January 12, 2017
Combined radiotherapy and immunotherapy improve efficacy in a murine lung cancer model - More information: Cancer CellDOI: 10.1016/j.ccell.2016.12.005 , www.cell.com/cancer-cell/fulltext/S1535-6108(16)30600-6
Aspirin Use Found to Lower Risk of Pancreatic Cancer Yale January 5, 2017
"The regular use of aspirin lowers the risk for pancreatic cancer by almost 50 percent, a new study in China led by the Yale School of Public Health finds."
New genes identified that regulate the spread of cancers MedicalXpress January 11, 2017
More information: Louise van der Weyden et al, Genome-wide in vivo screen identifies novel host regulators of metastatic colonization, Nature (2017). DOI: 10.1038/nature20792
A novel cancer immunotherapy shows early promise in preclinical studies MedicalXpress January 11, 2017
More information: A. Metelli et al, Surface Expression of TGF Docking Receptor GARP Promotes Oncogenesis and Immune Tolerance in Breast Cancer, Cancer Research (2016). DOI: 10.1158/0008-5472.CAN-16-1456
A surprise advance in the treatment of adult cancers MedicalXpress January 11, 2017
"A team of researchers at the Research Institute of the McGill University Health Centre (RI-MUHC) has found an epigenetic modification that might be the cause of 15% of adult cancers of the throat linked to alcohol and tobacco use."
More information: Impaired H3K36 methylation defines a subset of head and neck squamous cell carcinomas, Nature Genetics, nature.com/articles/doi:10.1038/ng.3757
Tumor-seeking salmonella treats brain tumors MedicalXpress January 11, 2017
More information: Nalini Mehta et al, Bacterial Carriers for Glioblastoma Therapy, Molecular Therapy - Oncolytics (2016). DOI: 10.1016/j.omto.2016.12.003
Expert Highlights Efficacy of KTE-C19 CAR T-Cell Therapy in Non-Hodgkin Lymphoma OncLive Jan 06, 2017
Immunotherapy in 2017 Elizabeth Jaffee, MD
“In 2017, I expect to see the development of new drugs that target additional immune checkpoints,” says Jaffee. One reason why almost 70 percent of cancers do not respond to checkpoint inhibitors is that the cancer cells inhibit different pathways that affect T-cell function. Therapeutics targeting immune-evasion mechanisms other than the PD-1/PD-L1 checkpoint, such as IDO, CD40, OX40, TIM-3, LAG-3, and KIR, are already in early clinical development. We will see them progress to clinical testing, alone or in combination with PD-1/PD-L1 drugs, and some of them may be approved or may come close to approval this year, Jaffee predicts."
FDA grants priority review for Bayer’s liver cancer treatment European Pharmaceutical Review 4 January 2017
Cancers evade immunotherapy by 'discarding the evidence' of tumor-specific mutations MedicalXpress January 5, 2017
"Results of an initial study of tumors from patients with lung cancer or head and neck cancer suggest that the widespread acquired resistance to immunotherapy drugs known as checkpoint inhibitors may be due to the elimination of certain genetic mutations needed to enable the immune system to recognize and attack malignant cells. The study, conducted by researchers on the cells of five of their patients treated at the Johns Hopkins Kimmel Cancer Center, is described online Dec. 28 in Cancer Discovery."
More information: Valsamo Anagnostou et al. Evolution of Neoantigen Landscape During Immune Checkpoint Blockade in Non-Small Cell Lung Cancer, Cancer Discovery (2016). DOI: 10.1158/2159-8290.CD-16-0828
Cancer Statistics, 2017 CA Cancer J Clin 2017
Halozyme's pancreatic cancer drug succeeds in mid-stage trial Reuters Jan 5, 2017
"Halozyme Therapeutics Inc said its lead experimental drug, in tandem with therapies from Celgene Corp and Eli Lilly and Co, succeeded in a mid-stage study involving patients with an advanced form of pancreatic cancer."
Halozyme jumps, then lands, on positive late-stage pancreatic cancer data FierceBiotech Jan 5, 2017
"These topline results come from a combined analysis of Stages 1 and 2, as well as Stage 2 alone, of its HALO 202 study using its med PEGPH20 in combination with Celgene’s cancer drug Abraxane (nab-paclitaxel) and Lilly’s Gemzar (gemcitabine) in stage IV pancreas cancer patients."
Artificial 'voice box' implant helps cancer patient speak MedicalXpress January 5, 2017
The report appears in the Jan. 5 issue of the New England Journal of Medicine.
Exploring Immunotherapy's Role in Osteosarcoma Cure December 30, 2016
Lipid metabolism is potential 'Achilles' heel' for cancer stem cells MedicalXpress January 3, 2017
More information: Lipid Desaturation Is a Metabolic Marker and Therapeutic Target of Ovarian Cancer Stem Cells, Cell Stem Cell, 2016.
Researchers uncover mechanism for cancer-killing properties of pepper plant MedicalXpress January 3, 2017
"The secret lies in a chemical called Piperlongumine (PL), which has shown activity against many cancers including prostate, breast, lung, colon, lymphoma, leukemia, primary brain tumors, and gastric cancer."
Chemo-brain among women with breast cancer is pervasive, study shows MedicalXpress December 29, 2016
More information: Cognitive Complaints in Survivors of Breast Cancer After Chemotherapy Compared With Age-Matched Controls: An Analysis From a Nationwide, Multicenter, Prospective Longitudinal Study. Journal of Clinical Oncology. DOI: 10.1200/JCO.2016.68.5826
Penn experts call for expansion of molecular imaging in precision cancer care MedicalXpress December 29, 2016
"New molecular imaging technologies can make it easier to diagnose, monitor, and treat cancers while potentially saving patients from undergoing therapies that are likely to be ineffective and playing a role in minimizing side effects, according to experts from the Abramson Cancer Center and the Perelman School of Medicine at the University of Pennsylvania. In a review published online today in JAMA Oncology, the Penn team says finding a way to use these techniques more widely in clinical settings should be a top priority."
SELECTED ONCOLOGY PUBLICATIONS 2016
Molecular imaging to promote precision oncology: a review JAMA Oncology December 29, 2016
"Molecular imaging to promote precision oncology: a review" Eric Topol
Brain Cancer’s Cholesterol Addiction May Offer New Treatment Strategy NCI December 16, 2016
"A new study suggests that brain cancer cells may depend on a constant supply of cholesterol from other brain cells"
Experimental brain cancer treatment is a success Time Health Dec 28, 2016
"The patient who tried it is still alive more than a year later"
"Impressive response to local immunotherapy for brain cancer using engineered T cells, N=1" Eric Topol
Copy number alterations unmasked as enhancer hijackers Nature Genetics 28 December 2016
"When copy number variants engender cancer, not by gene dosage, but via hijacking enhancers" Eric Topol
New Treatment Target Identified for Key Prostate Cancer Driver NCI April 22, 2016
Predicting throat cancer recurrence with a blood test MNT 19 December 2016
"Using a blood test to predict throat cancer recurrence"
Comparison of Regional and State Differences in Melanoma Rates in the United States2003 vs 2013 JAMA Dermatology December 28, 2016
"Where melanoma strikes in the United States" Eric Topol
Direct evidence for cancer-cell-autonomous extracellular protein catabolism in pancreatic tumors Nature Medecine Dec 26, 2016
"A new study suggests that cancer cells incorporate proteins in their microenvironment as a source of amino acids"
Genome-Wide Association Study for Anthracycline-Induced Congestive Heart Failure Clinical Cancer Research 19 December 2016
"A genetic biomarker was found for increased risk of anthracycline chemotherapy-induced cardiac damage"
The role of fatty acid β-oxidation in lymphangiogenesis Nature 26 December 2016
"For cancer to spread, fatty acid oxidation may act like fuel" Eric Topol
A Serum Biomarker May Predict Response to Immunotherapy Drugs That Target Immune Checkpoints Health Canal 26 December 2016
"Per a new study in @AACR: A serum biomarker may predict response to immunotherapy drugs that target immune checkpts"
Researchers develop automated melanoma detector for skin cancer screening MedicalXpress December 25, 2016
More information: Daniel S. Gareau et al. Digital imaging biomarkers feed machine learning for melanoma screening, Experimental Dermatology (2016). DOI: 10.1111/exd.13250
New precision medicine tool helps optimize cancer treatment MedicalXpress December 22, 2016
More information: Chengliang Dong et al, iCAGES: integrated CAncer GEnome Score for comprehensively prioritizing driver genes in personal cancer genomes, Genome Medicine (2016). DOI: 10.1186/s13073-016-0390-0
Number of deaths from smoking are > deaths from HIV + drugs + alcohol + car crashes + guns
Overweight affects DNA methylation MedicalXpress December 22, 2016
More information: Simone Wahl et al. Epigenome-wide association study of body mass index, and the adverse outcomes of adiposity, Nature (2016). DOI: 10.1038/nature20784
Metabolomics Study Reveals another Energy Source for Cancer Cells NCI October 20, 2016
"Study Reveals another Energy Source for Cancer Cells"
Straightening the Path from Human Genome to Human Benefit Abbvie December 19, 2016
"Mapping the human genome was only the beginning. Now, Tom Hudson is using that map to unearth new approaches to cancer."
Harnessing the U.S. Taxpayer to Fight Cancer and Make Profits The New york Times Health Dec 19, 2016
"Kite’s first drug, called KTE-C19, could help thousands of patients each year in the United States with certain blood cancers. If it succeeds, it could generate sales of $1 billion to $2 billion annually, according to Wall Street analysts, making it among the most lucrative drugs to come from government research."
Unexpected DNA-Binding Mechanism Suggests Ways to Block Enzyme Activity in Cancer GEN December 20, 2016
Scientists find new gene tool for predicting course of prostate cancer MedicalXpress December 20, 2016
More information: A four gene signature predictive of recurrent prostate cancer. Oncotarget. DOI: 10.18632/oncotarget.13837
FDA Grants Accelerated Approval to New Treatment for Advanced Ovarian Cancer Oncology Times December 19, 2016
"The FDA has granted accelerated approval to rucaparib (Rubraca) to treat women with a certain type of ovarian cancer. Rucaparib is approved for women with advanced ovarian cancer who have been treated with two or more chemotherapies and whose tumors have a specific gene mutation (deleterious BRCA) as identified by an FDA-approved companion diagnostic test."
A transistor-like pH nanoprobe for tumour detection and image-guided surgery Nature Biomedical Engineering 19 December 2016
"A nanoprobe to guide surgery for cancer" Eric Topol
Algorithms compete to predict recipe for cancer vaccine Nature 13 December 2016
"Could a battle of algorithms help us get to an individualized cancer vaccine?" Eric Topol
Immunotherapy in the Precision Medicine Era: Melanoma and Beyond PLOS Medecine December 13, 2016
"Insightful perspective on cancer immunotherapy, precision oncology" Eric Topol
Extracellular Vesicles in Cancer: Cell-to-Cell Mediators of Metastasis Cancer Cell 12 December 2016
"Challenging the dogma that cancer progresses to metastasis in a linear fashion" Eric Topol
Diversity and collaboration for effective immunotherapy Nature Medecine 2016
"Combo immunotherapy targeting different immune response arms can overcome tumors that escape single-path therapies"
Gene Identified that Drives Deadly Brain Cancer CheckOrphan December 12, 2016
Topical skin cream for treatment of basal cell carcinoma shows promise as an alternative to surgery MedicalXpress December 13, 2016
More information: Hywel C. Williams et al. Surgery Versus 5% Imiquimod for Nodular and Superficial Basal Cell Carcinoma: 5-Year Results of the SINS Randomized Controlled Trial, Journal of Investigative Dermatology (2016). DOI: 10.1016/j.jid.2016.10.019
Laboratory-on-a-chip technique simplifies detection of cancer DNA biomarkers Phys Org December 13, 2016
More information: "On-chip wavelength multiplexed detection of cancer DNA biomarkers in blood," Hong Cai, Matthew Stott, Damla Ozcelik, Joshua W. Parks, Aaron R. Hawkins and Holger Schmidt, Biomicrofluidics Dec. 15, 2016
Read more at: http://phys.org/news/2016-12-laboratory-on-a-chip-technique-cancer-dna-biomarkers.html#jCp
Cancer cells spread way earlier than thought, seeding metastases that cause most deaths STAT December 14, 2016
Unexpected activity of two enzymes helps explain why liver cancer drugs fail MedicalXpress December 13, 2016
For more information: Dual Shp2 and Pten Deficiencies Promote Non-alcoholic Steatohepatitis and Genesis of Liver Tumor-Initiating Cells Cell Reports 2016
New Liver Cancer Model Based on Counterintuitive Enzyme Activity GEN News Highlights Dec 14, 2016
"Lack of 2 types of enzymes can lead to liver disease and cancer"
"Together, our findings establish that simultaneous Tie2 activation and Ang2 inhibition form a powerful therapeutic strategy to elicit a favorable tumor microenvironment and enhanced delivery of a chemotherapeutic agent into tumors."
Supplement: Treating “Solid” Tumors with CAR T Cells Feature Articles GEN December 01, 2016
The Road to Developing Effective Cancer Immunotherapies Using CAR T Cells Has Been a Long and Sometimes Rocky One
"The pitfalls of using CAR T-cell therapy to treat solid tumors and how to address them was a key theme discussed by a number of researchers in November at CHI on Novel Immunotherapy Strategies, in Lisbon."
Even a Cigarette a Day Is Bad for Your Health the New York Times DEC. 7, 2016
"These findings, from a large study in JAMA Internal Medicine, provide further evidence that even the lowest levels of exposure to tobacco smoke are unsafe."
Nivolumab/Brentuximab Vedotin Combo Potential Second-Line Therapy in Relapsed/Refractory Hodgkin Lymphoma Targeted Oncology December 6, 2016
“The overall response rate to the combination of brentuximab vedotin and nivolumab as a second-line therapy for Hodgkin lymphoma was 90%,” Herrera said. “The complete response rate was 62%, and the partial response rate was 28%.”
Researchers Find New Biomarker for Brain Cancer Prognosis CheckOrphan December 07, 2016
""As an independent biomarker, SHOX2expression is as potent as the currently best and widely used marker known as IDH mutations," said Dr. Adi Gazdar, Professor of Pathology in the Nancy B. and Jake L. Hamon Center for Therapeutic Oncology"
Study identifies cells responsible for initiating and promoting metastasis in several types of human tumors MedicalXpress December 7, 2016
"A study headed by Salvador Aznar Benitah, ICREA researcher at the Institute for Research in Biomedicine (IRB Barcelona), and published today in Nature identifies metastasis-initiating cells through a specific marker, namely the protein CD36. This protein, which is found in the membranes of tumour cells, is responsible for taking up fatty acids. CD36 activity and dependence on lipid (fat) metabolism distinguish metastasis-initiating cells from other tumour cells."
More information: Gloria Pascual et al, Targeting metastasis-initiating cells through the fatty acid receptor CD36, Nature (2016). DOI: 10.1038/nature20791
Stem cell-based test predicts leukemia patients' response to therapy to tailor treatment MedicalXpress December 7, 2016
"Leukemia researchers at Princess Margaret Cancer Centre have developed a 17-gene signature derived from leukemia stem cells that can predict at diagnosis if patients with acute myeloid leukemia (AML) will respond to standard treatment."
More information: A 17-gene stemness score for rapid determination of risk in acute leukaemia, nature.com/articles/doi:10.1038/nature20598
Patient-derived induced pluripotent stem cells in cancer research and precision oncology Nature Medecine 06 December 2016
"A super review on induced pluripotent stem cells for cancer" Eric Topol
Protein that promotes 'cell-suicide' could revolutionise eye cancer treatment MedicalXpress December 6, 2016
New research from the University of Liverpool has identified the role of a specific protein in the human body that can help prevent the survival and spread of eye cancer, by initiating cancer 'cell-suicide'.
More information: Raheela Awais et al. p63 is required beside p53 for PERP-mediated apoptosis in uveal melanoma, British Journal of Cancer (2016). DOI: 10.1038/bjc.2016.269
AstraZeneca pill slashes lung cancer progression in study Reuters Health Dec 6, 2016
"AstraZeneca's pill Tagrisso cut the risk of lung cancer progressing by 70 percent compared to standard chemotherapy in a major clinical trial, lifting prospects for a drug that is key to the company's lofty long-term sales goals."
"Osimertinib had significantly greater efficacy than platinum therapy plus pemetrexed in patients with T790M-positive advanced non–small-cell lung cancer (including those with CNS metastases) in whom disease had progressed during first-line EGFR-TKI therapy. (Funded by AstraZeneca; AURA3 ClinicalTrials.gov number,"
Ibrutinib Shows Impressive 5-Year Results in CLL/SLL Targeted Oncology December 5, 2016
chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
CAR T-Cell Immunotherapy Proves a Plus in Treatment-Resistant Chronic Lymphocytic Leukemia GEN News Highlights December 5, 2016
"infusion of a highly targeted, experimental CD19-targeting chimeric antigen receptor (CAR) T-cell immunotherapy developed at Seattle's Fred Hutchinson Cancer Research Center."
"These are all heavily pretreated patients who've gone through many previous therapies," Dr. Turtle said. "It's very pleasing to see patients with refractory disease respond like this."
CD19-Targeting CAR T-Cell Immunotherapy Yields High Responses In Treatment-Resistant CLL CheckOrphan December 05, 2016
Novartis says 82 percent of leukemia patients in remission after CAR-T Reuters Health Dec 4, 2016
"Novartis said it plans to file early next year for U.S. Food and Drug Administration approval of CTL019."
Immune System, Unleashed by Cancer Therapies, Can Attack Organs The New York Times Dec 3, 2016
"Chuck Peal, 61, at home in Southbury, Conn. He developed acute-onset diabetes, as did other patients who received immunotherapy at Yale."
"Study leader Professor Sam Denmeade, from Johns Hopkins University School of Medicine, in Baltimore, United States, said: “We think the results are unexpected and exciting.”
He added: “Our goal is to shock the cancer cells by exposing them rapidly to very high followed by very low levels of testosterone in the blood.""
Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-years for 32 Cancer Groups, 1990 to 2015A Systematic Analysis for the Global Burden of Disease Study JAMA Oncology 2016
"A new opus on the global burden of cancer" Eric Topol
Noninvasive microscopy technique allows for spotting skin cancer in mitochondria MedicalXpress December 1, 2016
"A team of researchers from several institutions in the U.S. and one in Spain has developed a new way to test for skin cancer in patients—one that does not rely on taking a biopsy."
More information: D. Pouli et al. Imaging mitochondrial dynamics in human skin reveals depth-dependent hypoxia and malignant potential for diagnosis, Science Translational Medicine (2016). DOI: 10.1126/scitranslmed.aag2202
ARIAD Announces FDA Full Approval and Label Update for Iclusig® (ponatinib) CheckOrphan November 30, 2016
"ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that the U.S. Food and Drug Administration (FDA) has granted Iclusig®(ponatinib) full approval for the treatment of adult patients with chronic phase, accelerated phase, or blast phase chronic myeloid leukemia (CML)..."
Lung Cancer? What Patients Need to Know About Immunotherapy, with Leena Gandhi YouTube Nov 28, 2016
"In this webinar designed for patients and caregivers, Leena Gandhi, M.D., Ph.D., of NYU Langone, discusses current immunotherapy treatment options for patients with lung cancer, and the latest breakthroughs that are paving the way to for immunotherapy to help even more patients."
"The unique genomic features of testicular cancer: what makes them sensitive/resistant to Rx" Eric Topol
New imaging method can detect, monitor and guide treatment for, prostate cancer MedicalXpress November 30, 2016
"In the new study, the investigators developed a new antibody called 11B6 to target human kallikrein-related peptidase 2 (hK2), another antigen that indicates androgen receptor pathway activation. Unlike PSA, hK2 is specifically active only in the prostate and an aggressive type of breast cancer."
More information: "Internalization of secreted antigen–targeted antibodies by the neonatal Fc receptor for precision imaging of the androgen receptor axis," Science Translational Medicine, stm.sciencemag.org/lookup/doi/10.1126/scitranslmed.aaf2335
Summer Project Turns Into Leukemia Testing Breakthrough The New York Times Health Nov 28, 2016
"Researchers with a sample card with dried blood that can be used to test for chronic myeloid leukemia."
As revenue falls, a pioneer of cancer gene testing slams rivals with overblown claims STAT November 29, 2016
More Immunotherapy Options Approved for Lung Cancer NCI November 17, 2016
Atezolizumab (Tecentriq®) - Pembrolizumab (Keytruda®)
Erectile dysfunction drugs and skin cancer — should you worry? Harvard Heatlh Publications Updated August 22, 2016,
Scientists step closer to halting spread of lung cancer MedicalXpress November 25, 2016
"Researchers identified that a protein, called PAQR11, inside the 'cellular post office', receives a signal from another protein, called Zeb1; the communication between the two proteins prompts the transport of membrane sacks inside the Golgi.": alteration of the perimeter of the cancer cell leading to its movement.
Xiaochao Tan et al. Epithelial-to-mesenchymal transition drives a pro-metastatic Golgi compaction process through scaffolding protein PAQR11, Journal of Clinical Investigation (2016)
Rewiring cancers’ circuits – a new way to kill? Cancer Research UK November 24, 2016
"Our scientists reveal a potential new way to cut off tumours’ blood supply."
FDA Approves Daratumumab Triplets for Relapsed Myeloma OncLive Nov 21, 2016
"The FDA has approved daratumumab (Darzalex) in combination with lenalidomide (Revlimid) and dexamethasone or bortezomib (Velcade) and dexamethasone for patients with relapsed multiple myeloma"
DARZALEX® (DARATUMUMAB) Approved by U.S. FDA in Combination with 2 Standard of Care Regimens for the Treatment of Patients with Multiple Myeloma Who Have Received at least one Prior Therapy CheckOrphan November 23, 2016
Lung cancer: from metaphors to monumental progress Roche Nov 2016
"An explosion of Biomarker - Diversity"
Novel Urine Test May Predict High-Risk Cervical Cancer The ASCO Post 11/18/2016
"Investigators identified three genes associated with cervical cancer or abnormal-looking cells known to become cancerous: FKBP6, INTS1, and ZNF516. Using methylation as a value to diagnose malignancy, the three genes together showed a 90% sensitivity, and the test had an 88.9% specificity."
"As many other chemotherapeutic agents are also known to oxidatively stress cancer cells, we expect that cyst(e)inase will be highly efficacious in combination therapies with other ROS-inducing drugs such as bortezomib or or arsenic trioxide."
IBM peut détecter les cancers de la peau avec un smartphone ExpressBusiness 15 novembre 2016
Strategies to avoid treatment-induced lineage crisis in advanced prostate cancer Nature Reviews Clinical Oncology 2016
"Herein, we present a new clinical trial strategy designed to evaluate the potential of rapid drug cycling as an approach to delay the onset of resistance and treatment-induced lineage crisis in patients with metastatic castration-resistant prostate cancer."
Researchers uncover a survival mechanism in cancer cells MedicalXpress November 22, 2016
"In a paper published in Science (LINK) the researchers describe the mechanism by which cancer tumor cells become cancer stem cells that can sustain long-term growth."
C. M. Torres et al, The linker histone H1.0 generates epigenetic and functional intratumor heterogeneity, Science (2016)
Targeting Golgi Apparatus May Help Prevent Lung Cancer Metastasis GEN News Highlights November 22, 2016
"Researchers at the University of Texas MD Anderson Cancer Center report that the Golgi apparatus may play a role in how lung cancer metastasizes. Their study (“Epithelial-to-Mesenchymal Transition Drives a Pro-Metastatic Golgi Compaction Process through Scaffolding Protein PAQR11”) appears in the online issue of the Journal of Clinical Investigation."
Triple-Drug Chemotherapy With Topotecan Helps Preserve Vision Oncology Times Nov 10, 2016
"Revamping front-line multi-drug chemotherapy for retinoblastoma to include topotecan helped maintain high cure rates for eye cancer while preserving patients' vision and reducing their risk of treatment-related leukemia."
"Results of the St. Jude Children's Research Hospital study appeared online in the Journal of Clinical Oncology (2016; DOI:10.1200/JCO.2016.69.2996)"
CRISPR-Cas9 technique exploits pancreatic cancer cells' vulnerabilities to develop new treatments MedicalXpress November 22, 2016
"Using this revolutionary tool, the team of researchers probed the function of every single gene expressed by pancreatic cancer cells to determine that one of the receptors (Frizzled-5) is essential for the growth of mutant pancreatic cancer cells."
Zachary Steinhart et al. Genome-wide CRISPR screens reveal a Wnt–FZD5 signaling circuit as a druggable vulnerability of RNF43-mutant pancreatic tumors, Nature Medicine (2016)
New tool to track circulating cancer cells Phys Org November 22, 2016
"Monitoring circulating tumour cells, however, is a tremendous challenge as they are outnumbered in blood by healthy cells at a level of over 1 billion-to-1"
"Using magnetic nanoparticles, CTCs in blood samples were targeted based on proteins displayed on the cell surface, and separated based on the levels of the protein present"
Mahla Poudineh et al. Tracking the dynamics of circulating tumour cell phenotypes using nanoparticle-mediated magnetic ranking, Nature Nanotechnology (2016).
Biologists link levels of Mena protein to breast cancer cells' sensitivity to chemotherapy MedicalXpress November 22, 2016
"MIT biologists have identified a new biomarker that can reveal whether patients with a particularly aggressive type of breast cancer will be helped by paclitaxel (commercially known as Taxol), one of the drugs most commonly used to treat this cancer."
M. J. Oudin et al. Mena confers resistance to Paclitaxel in triple-negative breast cancer, Molecular Cancer Therapeutics (2016)
GlaxoSmithKline seeks U.S. approval for triple lung drug Reuters Health News Mon Nov 21, 2016
"GSK's triple inhaler, which is being developed with Innoviva, combines fluticasone, umeclidinium and vilanterol."
Blood test could predict best treatment for lung cancer MedicalXpress November 21, 2016
"Using copy number variants from circulating tumor cells to guide cancer Rx" Eric Topol
"By identifying differences in the patterns of genetic faults between patients, we now have a starting point to begin to understand more about how drug resistance develops in patients with this aggressive form of lung cancer."
Scientists create innovative drug design strategy to improve breast cancer treatment November 21, 2016
""Our structure-trapping approach to X-ray crystallography provides a molecular snapshot of how subtle changes to a compound series generate a range of graded activity profiles," said Research Associate Jerome C. Nwachukwu,"
See: Full antagonism of the estrogen receptor without a prototypical ligand side chain, Nature Chemical Biology 2016
"PREVENT supports development of the best ideas in cancer prevention intervention and biomarkers using NCI contract resources instead of direct funding. The program is a peer-reviewed pipeline that focuses on research needs that are not adequately addressed by the private sector."
FDA approves Bristol-Myers Squibb’s Opdivo as first Immuno-Oncology treatment European Pharmaceutical Review 17 November 2016
"The US Food and Drug Administration (FDA) has approved Bristol-Myers Squibb’s Opdivo (nivolumab) injection, for intravenous use, for the treatment of patients with recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN) with disease progression on or after platinum-based therapy."
A protein that defines the melanoma blueprint MedicalXpress November 18, 2016
"CPEB4, is therefore a main driver of the "intrinsic signature" that separates melanomas from other pathologies, concludes Soengas."
Lineage-specific roles of the cytoplasmic polyadenylation factor CPEB4 in the regulation of melanoma drivers Soengas & co-workers Nature Communications 2016
Chinese scientists become first to test CRISPR in humans, as ‘Sputnik 2.0’ begins FierceBiotech Nov 16, 2016
"China has beaten out U.S. academics and biotechs to become the first in testing new gene editing tech known as CRISPR-Cas9 in humans.
Reported in the Nature journal, Chinese scientists led by oncologist Lu You at Sichuan University in Chengdu, injected modified cells using CRISPR into a patient with a form of lung cancer at the West China Hospital."
Characteristics and Significance of the Pre-metastatic Niche Cancer Cell 2016
"Primary tumors create a favorable microenvironment, namely, pre-metastatic niche, in secondary organs and tissue sites for subsequent metastases."..."We highlight the significance of the pre-metastatic niche, and discuss potential implications and future research directions."
"the primary tumour emits signalling molecules that prime certain organs for the arrival of metastatic cells"
"When T cells enter tumor, they can become traitors" Eric Topol
Activating autophagy to potentiate immunogenic chemotherapy and radiation therapy Nature Reviews Clinical Oncology 2016
Black Raspberries Curb Oral Cancer Development in Animal Study AICR Nov 15, 2016
“Our study shows that feeding black raspberries to rats inhibits the development of oral cancer in an animal model,” said Steve Oghumu, PhD, a scientist at the Ohio State University and lead author of the study."
Eating Tomatoes Might Lower Your Risk of Prostate Cancer The Dealy Meal Nov 15, 2016
“Because lycopene is present in only a few foods, and approximately 85 percent of lycopene in the American diet comes from tomatoes and tomato products, people can really focus on eating tomato-containing foods,” John W. Erdman Jr., a professor at UIUC and the senior author on this research, told the American Institute for Cancer Research. “That’s a pretty easy way to reduce risk of cancer.”
Drug sensitivity of single cancer cells is predicted by changes in mass accumulation rate Nature Biotechnology October 10, 2016
Novartis leukemia drug wins FDA priority review Reuters Nov 14, 2016
"The FDA's fast-track designation reduces the review to six months for the medicine, also known as midostaurin, being tested against newly diagnosed FLT3-mutated acute myeloid leukemia (AML) and advanced systemic mastocytosis."
Preventing Cancer AACR Foundation 2016
"CancerProgress16 lists the top factors that increase cancer risk; tobacco use is number 1."
"Decades of research have led to the identification of numerous factors that increase a person’s risk of developing cancer. Many of these factors are related to lifestyle."
FDA Approves Nivolumab for Head and Neck Cancer OncLive Nov 10, 2016
"Nivolumab is now approved for patients with NSCLC, RCC, CHL, melanoma, as well as head and neck cancer"
"Typically, we recommend a proteasome inhibitor, such as Velcade or Kyprolis (carfilzomib), Revlimid and dexamethasone. This has become the standard of care for newly diagnosed patients."
How Alzheimer’s bad guy amyloid is being harnessed to fight cancer FierceBiotech Nov 10, 2016
De novo design of a biologically active amyloid Science 11 Nov 2016
"Gallardo et al. designed a peptide based on an amyloidogenic sequence in the vascular endothelial growth factor receptor VEGFR2. The peptide induced VEGFR2 to form aggregates with features characteristic of amyloids. Amyloids were toxic only in cells that required VEGFR2 activity, suggesting that the toxicity was due to loss of function of VEGFR2, rather than to inherent toxicity of the aggregates. The peptide inhibited VEGFR2-dependent tumor growth in a mouse tumor model."
Tobacco linked to 40 percent of US cancers MedicalXpress November 10, 2016
"Lung cancer, acute myeloid leukemia, and tumors of the mouth and throat, voice box, esophagus, stomach, kidney, pancreas, liver, bladder, cervix, colon and rectum are all caused by tobacco use, according the report by the US Centers for Disease Control and Prevention."
Bristol-Myers' Opdivo succeeds in key stomach cancer study Reuters Nov 10, 2016
"Opdivo met the main study goal of overall survival in patients who failed to respond to or are intolerant of standard chemotherapy"
Emerging Strategies for Developing Next-Generation Protein Therapeutics for Cancer Treatment Trends in Pharmaceutical Sciences 2016
Scientists develop computer models to predict cancer cell network activity MedicalXpress November 9, 2016
"InFlo works by assessing gene activity levels in tissue samples and predicting corresponding protein levels. It then uses statistical probabilities and other mathematical models to build activity webs showing how the proteins interact."
Increased protein activity makes bowel cancer drug resistant Drug Target Review 2016
"New protein found is key to drug resistant bowel cancer"
Shapeshifters in cancer: How some tumor cells change phenotype to evade therapy Nature Medicine 2016
Cancer cells hijack DNA repair networks to stay alive, study shows MedicalXpress November 8, 2016
""We expected to see DNA repair proteins, but seeing Polη* was really unexpected as it was known to be activated only in cells that were damaged by UV light, which we did not use in our experiments. Its role in the ALT** pathway is completely independent of how we think of it normally," said O'Sullivan. Knowing the molecular players in the ALT pathway opens up a whole new area of research and many potential drug targets, according to O'Sullivan."
*DNA polymerase η **alternative lengthening of telomeres (ALT)
T Minus, T Plus Differences in immune cells’ wiring indicate possible gene-editing targets Harvard Medical School October 27, 2016
"A deeper understanding of immune cells may lead to new cancer treatment targets"
"The findings of the two studies point to the need for a comprehensive atlas of the regulatory regions that are active in exhausted and functional T cells, he continued. Such a guide would provide targets for rewiring T cells with genetic engineering or epigenetic drugs to make them more effective cancer killers."
Domain swaps lessen autoimmunity in TCR GeneTherapy GEN November 8, 2016
"To prevent TCR mispairing and improve the safety of TCR gene therapy, researchers based at the California Institute of Technology have developed a new kind of TCR-engineered T cell. It is the result of a new technique—domain swapping."
Gold nanoparticles help deliver lethal one-two punch to cancer Cancer Research UK 8 November 2016
"TAGGING gold nanoparticles with a small dose of radiation has helped researchers trace the precious metal as it delivers a drug right into the heart of cancer cells, according to new laboratory research* being presented at the 2016 National Cancer Research Institute (NCRI) Cancer conference."
Genetically engineering disease-fighting cells: New technique improves the safety of cancer immunotherapy MedicalXpress November 8, 2016
"The technique, called domain swapping, was developed in the laboratory of David Baltimore, president emeritus and the Robert Andrews Millikan Professor of Biology. A paper describing the findings appears in the November 8 issue of the journal eLife."
Michael T Bethune et al, Domain-swapped T cell receptors improve the safety of TCR gene therapy, eLife (2016)
Adjuvant Ipilimumab Improves Survival in High-Risk Melanoma The ACO Post October 25, 2016
"“Ipilimumab as adjuvant therapy brings a significant improvement in overall survival and has a favorable risk/benefit ratio. It clearly represents a serious option for patients with stage III disease,” Dr. Eggermont commented." - Toxicity a concern
Tumour-associated mesenchymal stem/stromal cells: emerging therapeutic targets Nat Rev Drug Disc 2016
Low vitamin D levels linked to increased risk of bladder cancer MedicalXpress November 8, 2016
"Vitamin D deficiency is associated with an increased risk of developing bladder cancer, according to a systematic review of seven studies presented today at the Society for Endocrinology annual conference in Brighton. Though further clinical studies are needed to confirm the findings, the study adds to a growing body of evidence on the importance of maintaining adequate vitamin D levels."
Atezolizumab Combos Highly Effective for Advanced Melanoma OncLive Nov 07, 2016
"The addition of the PD-L1 inhibitor atezolizumab (Tecentriq) to the MEK inhibitor cobimetinib (Cotellic) and the BRAF inhibitor vemurafenib (Zelboraf) induced a high response rate for patients with BRAF-mutant unresectable melanoma,"
"The great majority of patients are benefiting, and benefiting a lot."
"The combination of atezolizumab, cobimetinib, and vemurafenib had a manageable safety profile in patients with BRAF V600-mutant melanoma,
Deux rapports alertent sur le risque d'explosion de la mortalité par cancer Sciences et Avenir 02.11.2016
"la hausse de la mortalité s'expliquerait par l'augmentation de la fréquence de "facteurs de risque de cancer connus liés à la transition économique rapide comme l'inactivité physique, une mauvaise alimentation, l'obésité, et des facteurs reproductifs", notamment le fait de procréer plus tardivement"
Cancer deaths among women to rise 60% by 2030, new reports warn theguardian 2 November 2016
"American Cancer Society and Lancet studies point to devastating increases, mostly in poorer countries, with breast cancer diagnoses set to almost double"
Cancer : explosion du nombre de décès chez les femmes Le Monde 02.11.2016
Health, equity, and women's cancers The Lancet November 1, 2016
Recurrence Is Twice as Sensitive as CEA Test The ASCO Post 26/10/2016
"In a new report published by Young et al in Cancer Medicine, a two-gene circulating tumor DNA (ctDNA) blood test for postsurgical monitoring of colorectal cancer (CRC) recurrence has been shown to detect twice the number of recurrence cases as carcinoembryonic antigen (CEA) testing,"
"The test measures the presence of BCAT1 and IKZF1 gene methylation, a chemical modification associated with tumor growth and invasion."
Molecular and Biochemical Aspects of the PD-1 Checkpoint Pathway N Engl J Med 2016
"A super review on #cancer immunotherapy checkpoint inhibitors" Eric Topol
Breast Cancer kills one woman every 75 seconds The Times of India Nov 4, 2016
Researcher develops safer gene therapy MedicalXpress November 4, 2016
"Grant Trobridge, a Washington State University Spokane associate professor of pharmacy, has developed a way to reduce the development of cancer cells that are an infrequent but dangerous byproduct of gene therapy."
Jonah D. Hocum et al, Retargeted Foamy Virus Vectors Integrate Less Frequently Near Proto-oncogenes, Scientific Reports (2016).
Genetic interrogation of circulating multiple myeloma cells at single-cell resolution Science Translational Medicine 02 Nov 2016
"Lohr et al. now demonstrate that circulating tumor cells in peripheral blood of multiple myeloma patients can provide the same genetic information as bone marrow samples, and sometimes more."
15 cancer symptoms women often ignore JNCI 2016
Smoking a pack a day for a year causes 150 mutations in lung cells MedicalXpress November 3, 2016
"Scientists have measured the catastrophic genetic damage caused by smoking in different organs of the body and identified several different mechanisms by which tobacco smoking causes mutations in DNA. Researchers at the Wellcome Trust Sanger Institute, the Los Alamos National Laboratory and their collaborators found smokers accumulated an average of 150 extra mutations in every lung cell for each year of smoking one packet of cigarettes a day."
"Other organs were also affected, with the study showing that a pack a day led to an estimated average 97 mutations in each cell in the larynx, 39 mutations for the pharynx, 23 mutations for mouth, 18 mutations for bladder, and 6 mutations in every cell of the liver each year"
"Mutational signatures associated with tobacco smoking in human cancer," Science 2016
"Fumer un paquet de cigarettes par jour pendant 1 an génèrent 150 mutations dans le cellules pulmonaires"
PD-1–PD-L1 immune-checkpoint blockade in B-cell lymphomas Nature Reviews Clinical Oncology 2016
Single-cell analysis supports a role for cancer stem cells in brain tumor growth MedicalXpress November 2, 2016
"Our work strongly supports that cancer stem cells are the main source of growth in these tumors and, as such, should be considered promising targets for treatment," says Mario Suvà, MD, PhD, of the MGH Department of Pathology, co-senior author of the Nature paper.
Fulminant Myocarditis with Combination Immune Checkpoint Blockade N Engl J Med 2016
"We report the cases of two patients with melanoma in whom fatal myocarditis developed after treatment with ipilimumab and nivolumab."
Life saving Cancer Drugs May in Rare Cases Threaten the Heart The New York Times nov 2, 2016
"So far, fewer than 1 percent of patients taking these medicines — called checkpoint inhibitors — have developed heart trouble."
"Four checkpoint inhibitors are on the market: ipilimumab (brand name Yervoy), nivolumab (Opdivo), pembrolizumab (Keytruda) and atezolizumab (Tecentriq)."
"This technology supported study of potential toxic effects of electronic cigarettes"
Fighting cancer with the power of immunity - New treatment elicits two-pronged immune response that destroys tumors in mice. MIT October 24, 2016
"Harnessing the body’s own immune system to destroy tumors is a tantalizing prospect that has yet to realize its full potential. However, a new advance from MIT may bring this strategy, known as cancer immunotherapy, closer to becoming reality. In the new study, the researchers used a combination of four different therapies to activate both of the immune system’s two branches, producing a coordinated attack that led to the complete disappearance of large, aggressive tumors in mice."
State-Level Cancer Mortality Attributable to Cigarette Smoking in the United States JAMA Intern Med. October 24, 2016
What proportion of cancer deaths are attributable to cigarette smoking in each US state?
Dendritic Cells and Cancer Immunity Trends in Immunology 2016
Breast Cancer's Complexity Pushes Researchers to Look Beyond the Genome OncLive October 25, 2016
"There is hope that shifting focus away from individual mutations and back to the cancer cell as a whole will help to bridge the gap between genomics and clinical action."
"Among patients with platinum-sensitive, recurrent ovarian cancer, the median duration of progression-free survival was significantly longer among those receiving niraparib than among those receiving placebo, regardless of the presence or absence of gBRCA mutations or HRD status, with moderate bone marrow toxicity."
30% of Cancer Deaths Are Due to Smoking TIME Oct. 24, 2016
"About a third of cancer deaths in American men and a quarter in women are linked to cigarette smoking, finds a new study published in JAMA Internal Medicine."
State-Level Cancer Mortality Attributable to Cigarette Smoking in the United States JAMA Intern Med. October 24, 2016
"Conclusions and Relevance The proportion of cancer deaths attributable to cigarette smoking varies substantially across states and is highest in the South, where up to 40% of cancer deaths in men are caused by smoking. Increasing tobacco control funding, implementing innovative new strategies, and strengthening tobacco control policies and programs, federally and in all states and localities, might further increase smoking cessation, decrease initiation, and reduce the future burden of morbidity and mortality associated with smoking-related cancers."
"A new compound, discovered jointly by international pharmaceutical company Servier, headquartered in France, and Vernalis (R&D), a company based in the UK, has been shown by researchers at the Walter and Eliza Hall Institute and Servier to block a protein that is essential for the sustained growth of up to a quarter of all cancers. Associate Professor Guillaume Lessene, Walter and Eliza Hall"
New Compound Shows Promise in Treating Multiple Human Cancers CheckOrphan October 21, 2016
"The research presents a new way to efficiently kill these cancerous cells and holds promise for the treatment of blood cancers such as acute myeloid leukemia, lymphoma and multiple myeloma, as well as solid cancers such as melanoma and cancers of the lung and breast. It is published online today in the journal Nature. The Servier compound - S63845 - targets a protein of the BCL2 family, called MCL1, which is essential for the sustained survival of these cancer cells."
Onion compound suppresses ovarian cancer cell proliferation MNT 22 October 2016
Epithelial Ovarian Cancer (EOC): First study to report anti-ovarian cancer effect of onionin A, or ONA. Scientific Reports 2016
CRISPR Screen Finds New Potential Leukemia Drug Target GEN News Highlights October 19, 2016
"This research has led to the identification of many potential gene targets for future Acute Myeloid Leukemia (AML) therapy”
"The leukemia genome: 500 genes that are essential for cancer cell survival, including more than 200 genes for which drugs could be designed"
"It has recently become apparent that the gut microbiota modulates the response to cancer therapy. In this issue of Immunity, Daillère et al. (2016) identified two bacterial species potentiating the anti-tumor effect of cyclophosphamide that are kept in check by the sensor NOD2."
"the gut microbiota modulates the response to cancer therapy"_"two bacterial species potentiating the anti-tumor effect of cyclophosphamide"
Self-renewable cancer killer cells could be key to making immunotherapy work MedicalXpress October 26, 2016
"A small molecule that can turn short-lived 'killer T-cells' into long-lived, renewable cells that can last in the body for a longer period of time, activating when necessary to destroy tumour cells, could help make cell-based immunotherapy a realistic prospect to treat cancer."
"A small molecule (2-hydroxyglutarate, or 2-HG) that can turn short-lived 'killer T-cells' into long-lived, renewable cells..."
Epigenetic drug discovery: breaking through the immune barrier Nature Reviews Drug Discovery 2016
"These agents will inevitably begin to move into clinical trials for use in patients with immune-mediated diseases."
Melanoma Immunotherapy Significantly Improved with Peptide Bath GEN News Highlights October 17, 2016
“Efficacy of Adoptive T-cell Therapy Is Improved by Treatment with N-Acetyl Cysteine, Which Limits Activation-Induced T-cell Death”
A novel noninvasive imaging probe for fast and sensitive detection of cancer MedicalXpress October 21, 2016
"This research demonstrates that the technology combining BRET and ubiquitin-proteasome system (UPS) is a breakthrough approach for fast and highly sensitive detection of tumors."
"Opening new avenues in molecular Imaging for fast and sensitive detection of cancer"
Macrophage Metabolism Controls Tumor Blood Vessel Morphogenesis and Metastasis Cell Metabolism 2016
"Our data provide a functional link between tumor-associated macrophage (TAM) metabolism and tumor angiogenesis"
Harnessing NK Cell Memory for Cancer Immunotherapy Trends in Immunology 2016
"Due to their ability to kill cancer cells and produce proinflammatory cytokines, natural killer (NK) cells have long been of clinical interest for their antitumor properties. The recent discovery of NK cell memory demonstrates that NK cell functions, and potentially antitumor responses, can be enhanced long term."
Leveraging the immune system to treat advanced thyroid cancers The Lancet Diabetes & Endocrinology 2016
Scientists build a better cancer drug to pass through blood-brain barrier MedicalXpress October 20, 2016
"In efforts to develop new treatments for brain cancer, scientists from Johns Hopkins Drug Discovery and the Kimmel Cancer Center's Bloomberg~Kimmel Institute for Cancer Immunotherapy report they have altered the structure of an experimental drug that seems to enhance its ability to slip through the mostly impermeable blood-brain barrier. Results of their proof-of-concept experiments in monkeys, published Aug. 25 in the Journal of Medicinal Chemistry, show a tenfold better delivery of the drug to the brain compared with the rest of animals' bodies"
Identification of genome-wide cisplatin cross-linking sites with DNA base resolution Phys Org October 21, 2016
"Chinese team of scientists have now set up a universal, genome-wide assay system to detect the specific cisplatin action sites, In the journal Angewandte Chemie the scientists introduce their system and report initial results, which support the notion that the mitochondrial genome is one of cisplatin's main targets."
Cisplatin is widely used agents in Cancer Chemotherapy "a universal, genome-wide assay system to detect the specific cisplatin action sites"
Checkpoint Inhibitors Benefit Lung Cancer Patients in Clinical Trials Cancer Research Institute October 14, 2016
"Merck revealed results of two clinical trials that treated lung cancer patients with immunotherapy and could pave the way for its use as a first-line treatment option. In both trials, patients with metastatic and previously untreated non-small cell lung carcinoma (NSCLC) benefited from treatment with checkpoint blockade using the anti-PD-1 drug pembrolizumab (Keytruda). The results from the trials were published in the New England Journal of Medicine and The Lancet."
Common prostate cancer treatment linked to later dementia ecancernews 14 Oct 2016
"A new retrospective study of patient medical records suggests that men with prostate cancer who are treated with testosterone-lowering drugs are twice as likely to develop dementia within five years as prostate cancer patients whose testosterone levels are not tampered with." JAMA Oncology 2016 University of Pennsylvania
Leukemia cell movement gives clues to tackling treatment-resistant disease MedicalXpress October 17, 2016
"T cell acute leukaemia exhibits dynamic interactions with bone marrow microenvironments" by E.D. Hawkins et al. Nature 2016
Study finds a new way that tobacco smoke can cause cancer MedicalXpress October 17, 2016
"A recent study led by University of Kentucky researchers illuminates a new way that tobacco smoke may promote the development of lung cancer: inhibiting a DNA repair process called nucleotide excision repair (NER). The results of the study were published in the journal PLoS ONE."
Study finds a new way that tobacco smoke can cause cancer: inhibiting nucleotide excision repair (NER).
"As adjuvant therapy for high-risk stage III melanoma, ipilimumab at a dose of 10 mg per kilogram resulted in significantly higher rates of recurrence-free survival, overall survival, and distant metastasis–free survival than placebo. There were more immune-related adverse events with ipilimumab than with placebo"
The drug industry’s answer to opioid addiction: More pills The Washington Post October 16
"The story of OIC (opioid-induced constipation ) illuminates the opportunism of pharmaceutical innovators and the consequences of a heavily drug-dependent society. Six in 10 American adults take prescription drugs, creating a vast market for new meds to treat the side effects of the old ones."
"Opioid prescriptions alone have skyrocketed from 112 million in 1992 to nearly 249 million in 2015"
"Testing negative for colon cancer with this test does not necessarily prove the patient doesn’t have any precancerous growths, called polyps, or other signs of early colon cancer. This test detects late-stage cancers more successfully than it does early stages, but by then it might be too late to get treatment." Dr Chan associate professor of medicine at Harvard Medical School and a practicing gastroenterologist at Massachusetts General Hospital
"Researchers identified 14 genes regulating genome integrity that were consistently overexpressed in a wide variety of cancers"
A Potential New Biomarker for Cancer Patient Prognosis Oncology Times October 10, 2016
"Berkeley Lab researchers identified 14 genes regulating genome integrity that were consistently overexpressed in a wide variety of cancers. They then created a scoring system based upon the degree of gene overexpression. For several major types of cancer, including breast and lung cancers, the higher the score, the worse the prognosis. Perhaps more importantly, scores could accurately predict patient response to specific cancer treatments."
“We were surprised to find such a strong correlation between gene expression score & things like whether the patient survived 5 years later” Gary H. Karpen
Lung Cancer Treatment: Keytruda Better Than Chemotherapy In Patients With Non-Small Cell Lung Cancer TECH TIMES 16 October 2016
"The study, which was published in New England Journal of Medicine on Oct. 9 NEJM 2016, involved patients with non-small cell lung cancer (NSCLC) whose tumor had not yet spread to other parts of the body and who received no prior treatment."
"Our new data suggest that KEYTRUDA treatment can offer meaningful improvement over chemotherapy in a broad array of patients." Merck president Roger Perlmutter
New study combines laser therapy and craniotomy to treat large, previously inoperable brain tumours ecancernews The latest oncology headlines October 14, 2016
"A new paper in the journal Neurosurgical Focus finds the use of laser beneficial for the removal of large, "inoperable" glioblastoma (GBM) and other types of brain tumours."
Rekindling cancer vaccines Nature Biotechnology, 34, 1019-1024, 2016
"Interest in cancer vaccines is being reignited by a greater understanding of tumor immunology and the potential of combining immunogens with new breakthrough immunotherapies."
Drugs combination 'could create effective anti-kidney cancer weapon' INDEPENDENT 9 October 2016
"Scientists found that 40 per cent of patients treated with nivolumab and ipilimumab experienced a significant reduction in the size of their tumours." "The CheckMate -016 study was an early Phase I trial chiefly designed to investigate doses and side effects."
"The same combination of drugs has already been approved for NHS patients with advanced melanoma skin cancer."
L'immunothérapie bouleverse la prise en charge du cancer avancé du poumon Le Figaro 13/10/2016
Immunothérapie : l'inquiétante inflation du prix des thérapies innovantes Le Figaro 13/10/2016
L'immunothérapie, «un tremblement de terre dans le traitement des cancers avancés» Le Figaro 13/10/2016
Genomic analysis allows researchers to identify three subtypes of prostate cancer Stanford Medecine October 6, 2016
"The investigators’ statistical clustering analysis identified three distinct patient groups based on 100 key genes"
VIDEO: Pembrolizumab may ‘irrevocably alter’ the treatment landscape of NSCLC Healio HemOnc today Oct 14, 2016
“I would suspect that, sometime toward the end of this year or early 2017, pembrolizumab (Keytruda, Merck) will garner approval as a single agent in this specific population,” Corey J. Langer, MD, director of thoracic oncology at University of Pennsylvania Abramson Cancer Center and professor of medicine at the Hospital of the University of Pennsylvania
Cancer Type: Brain (and spinal cord) tumours - Open - Phase 2 - Supported by Bristol-Myers Squibb & Ono Pharmaceuticals Co. Ltd
Mammograms more likely to cause unneeded treatment than to save lives STAT October 12, 2016
"for every 1 woman in whom mammography finds a dangerous tumor, 4 are diagnosed & treated for a tumor that would never have harmed them" NEJM 2016
Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer NEJM October 9, 2016
"In patients with advanced NSCLC and PD-L1 expression on at least 50% of tumor cells, pembrolizumab was associated with significantly longer progression-free and overall survival and with fewer adverse events than was platinum-based chemotherapy."
Cardiovascular Toxic Effects of Targeted Cancer Therapies Javid J. Moslehi, M.D N Engl J Med 2016; 375:1457-1467
"Agents targeting signaling pathways in cancer cells are less specific than advertised. A number of these agents induce cardiovascular toxic effects ranging from decreased ejection fraction to atrial arrhythmias."
"A brain-penetrant LXR agonist kills GBM cells in a cholesterol-dependent fashion"
Depriving deadly brain tumors of cholesterol may be their Achilles' heel MedialXpress October 13, 2016
"a potential alternative method for treating glioblastomas (GBM), the most common and most aggressive form of brain cancer" Cancer Cell 2016
"These findings challenge the current progression model of pancreatic cancer and provide insights into the mutational processes that give rise to these aggressive tumours."
Drug sensitivity of single cancer cells is predicted by changes in mass accumulation rate Nature Biotechnology 2016 Published online 10 October 2016
"MAR measurement is a promising approach for directly assaying single-cell therapeutic responses and for identifying cellular subpopulations with phenotypic resistance in heterogeneous tumors."
"Drug response assay to single cancer cells"
"Understanding PD-L1 status—an important step toward understanding certain cancers."
"Not all patients have the same likelihood of responding to PD-1/PD-L1 pathway inhibition": High PD-L1 expressers & Low PD-L1 expressers
Genetic signature linked to cancer prognosis identified MedicalXpress October 10, 2016
Edoardo Gaude et al, Tissue-specific and convergent metabolic transformation of cancer correlates with metastatic potential and patient survival, Nature Communications (2016
"The researchers found that genes related to the OXPHOS pathway - a metabolic pathway in the cell's mitochondria that provides energy to the cell - were significantly down-regulated in the tumour cells from patients with poor clinical outcome. Furthermore, suppression of OXPHOS genes was linked to metastasis, where the cancer spreads to other parts of the body and is linked to even poorer prognosis. Although the link between OXPHOS genes and cancer survival has been found only to be an association at this stage, these results suggest that mitochondrial function might play an important role in metastasis and, therefore, patient prognosis."
Microsoft veut le guérir le cancer dans 10 ans grâce à des algorithmes TENDANCE 23 septembre 2016
Doctors grapple with best use of potent new cancer drugs Reuters Mon Oct 10, 2016
A radical revision of human genetics Nature 2016
Why many ‘deadly’ gene mutations are turning out to be harmless.
Vitamins A and C help erase cell memory Phys Org Oct 12, 2016
"Vitamins A and C aren't just good for your health, they affect your DNA too. Researchers at the Babraham Institute and their international collaborators have discovered how vitamins A and C act to modify the epigenetic 'memory' held by cells; insight which is significant for regenerative medicine and our ability to reprogramme cells from one identity to another. The research is published today in Proceedings of the National Academy of Science (PNAS 2016)."
"Retinol and ascorbate drive erasure of epigenetic memory and enhance reprogramming to naïve pluripotency by complementary mechanisms"
"This research provides an important understanding in order to progress the development of cell treatments for regenerative medicine"
Three in four people don’t know there’s a link between obesity and cancer Cancer Research UK
Le surpoids et l'obésité augmentent le risque de développer 13 types de cancers Source Cancer Research UK
Merkel cell carcinoma: “we now have two new possible immunotherapies": pembrolizumab (Keytruda®) & Avelumab (Merck KGaA/Pfizer)
“Two new possible immunotherapies that seem to not only get responses in some patients, but the responses seem to be quick and quite durable”
FDA grants priority review for Genmabs’ daratumumab to treat relapsed multiple myeloma European Pharmaceutical Review 12 October 2016
"The US Food and Drug Administration (FDA) has granted priority review to the supplemental biologics license application (sBLA) for the use of Genmab’s Daratumumab (darzalex) in combination with lenalidomide and dexamethasone, or bortezomib and dexamethasone, for the treatment of patients with multiple myeloma who have received at least one prior therapy."
"The results suggest that EMT reprograms carcinoma cells into pericyte-like cells that are essential for tumor vascular stabilization, thus revealing a new promalignant effect of EMT."
"This study thus proposes a previously unrecognized role for Epithelial-to-mesenchymal transition (EMT) in cancer."
Formation of new chromatin domains determines pathogenicity of genomic duplications Nature 538, 265-269, 2016
"In conclusion, we propose a novel approach to discovering potential cancer-driving mutations in noncoding regions."
MicroRNA specifically kills cancer cells with common mutation ecancernews 6 October 2016
"A potential therapeutic target for the eradication of KRAS-driven cancers"
A new strategy for choosing cancer drugs MIT News October 10, 2016
Device can predict tumor responses by measuring cell growth after drug exposure.
"The researchers successfully tested this approach with a very aggressive type of brain cancer called glioblastoma and a type of blood cancer known as acute lymphoblastic leukemia. They reported their results in the Oct. 10 issue of Nature Biotechnology."
Device can predict tumor responses by measuring cell growth after drug exposure.
"One major advantage of this technique is that it can be done with very small numbers of cells."
A study of motivations and expectations of patients seen in phase 1 oncology clinics Cancer 26 September 2016
"Patients considering Phase 1 oncology clinicaltrials may have unrealistic expectations of treatment benefit"
Discovery of Dual Inhibitors of MDM2 and XIAP for Cancer Treatment Cancer Cell, 30, 623-636, 2016
"MDM2/XIAP inhibitors exhibit anticancer activity in vitro and in animal models"
SOX2 Is the Determining Oncogenic Switch in Promoting Lung Squamous Cell Carcinoma from Different Cells of Origin Cancer Cell, 30, 519-532, 2016
"We show that multiple cell types in lung can give rise to LSCC, with different growth patterns in the central and peripheral lung."
Novartis edges closer to market, rival Ibrance with latest PhIII data update FierceBiotech Oct 10, 2016
Ribociclib PhIII: "for women with HR+/HER2- advanced breast cancer,”
Exelixis and Pfizer drugs compete in kidney cancer trial Reuters Health News Oct 10, 2016
"Exelixis's drug Cabometyx outperformed Pfizer's Sutent in a clinical study for the treatment of metastatic kidney cancer, suggesting it has the potential to become a first-line treatment"
New precision medicine trial targets pancreatic cancer STAT October 4, 2016
Precision Promise trial: "the first large-scale precision medicine trial for pancreatic cancer."
Cancer immunotherapy is moving fast. Here’s what you need to know The Washington Post September 28, 2016
Checkpoint Inhibitors "The Food and Drug Administration has cleared four checkpoint inhibitors for adults: Yervoy, also known as ipilimumab; Keytruda, or pembrolizumab; Opdivo, or nivolumab, and Tecentriq, or atezolizumab. The drugs are approved for malignancies including melanoma and Hodgkin lymphoma, as well as lung, kidney and bladder cancer. The treatments also are being tested in a wide range of other cancers."
"The Food and Drug Administration is likely to approve the first CAR T-cell treatment next year or in 2018"
Bristol trumpets Opdivo quality-of-life data ahead of Keytruda head and neck cancer showdown FiercePharma Oct 9, 2016
"Regulatory authorities are evaluating BMS' Opdivo in head & neck cancer based on impressive survival rates it posted in a Ph III study"
Dabrafenib, trametinib improve 3-year OS in advanced BRAF–mutated melanoma HemOnc today October 9, 2016
“This confirms the improved outcomes after this additional follow-up with dabrafenib+trametinib vs vemurafenib, despite the crossover,”
Niraparib Highly Effective as Maintenance Therapy for Recurrent Ovarian Cancer OncLive Oct 08, 2016
"Niraparib significantly improved all endpoints across a broad patient population, representing 70% of all ovarian cancer patients,"
ASCEND-5: ceritinib prolongs PFS vs chemotherapy (5.4 vs 1.6 months) in ALK-rearranged NSCLC previously treated with crizotinib NatureRevClinOncol October 2016
'Unprecedented' Tecentriq data sets stage for Roche lung cancer battle with Merck, BMS FiercePharma Oct 9, 2016
That survival benefit was “pretty similar” among those patients who expressed PD-L1 and those who didn’t, Chen said, suggesting that “not only you get a benefit in patients who have preexisting immunity," but patients who don’t “have evidence of preexisting immunity can get a survival benefit” as well.
"Roche has some new Tecentriq data that could soon help it break into the lung cancer space"
UDPATE2: Novartis' Ibrance challenger cuts breast cancer progression risk by 44% FiercePharma Oct 7, 2016
Novartis challenges Pfizer with strong breast cancer drug data Reuters Health News Oct 8, 2016
"Novartis' ribociclib (1) works in a similar way to Ibrance (1) and is set to be second to market in the category. It is expected to go on sale next year, ahead of Eli Lilly's rival abemaciclib." "(1) Both drugs are designed for patients whose tumors grow in response to estrogen and whose cancer is not caused by the HER2 protein."
Drug trio shows major promise against myeloma MedicalXpress October 7, 2016
"Daratumumab, Bortezomib, and Dexamethasone" significantly boost patients' chances of a response and even recovery for Multiple Myeloma_NEJM 2016
CRISPR/Cas9 : comment modifier les génomes va changer la société The Conversation 4 octobre 2016
"En juin 2016, le NIH a donné son accord pour porter le premier essai clinique utilisant CRISPR/Cas9 sur l’humain" en cancérologie
First CRISPR clinical trial gets green light from US panel Nature 22 June 2016
Cancer_ Premier Essai Clinique Utilisant CRISPR/Cas9_First CRISPR clinical trial_green light Nature News & Comment
Microsoft veut le guérir le cancer dans 10 ans grâce à des algorithmes Tendance 23 septembre 2016
"Microsoft s'est mis l'ambitieux objectif de guérir tous types de cancers, grâce à une équipe de 150 chercheurs au Royaume-Uni."
ROCHE ESMO16 Basel, 03 October 2016
First phase III data on Roche’s TECENTRIQ (atezolizumab) to feature at the 2016 European Society for Medical Oncology (ESMO) Congress
• Superiority results from the phase III OAK study comparing Tecentriq® to chemotherapy in a difficult to treat type of lung cancer will be highlighted at the ESMO Presidential Symposium
Cancer du Poumon_Atezolizumab – commercialisé sous l'appellation Tecentriq® – est reconnu comme une « percée thérapeutique » aux Etats-Unis
RedHill Biopharma commences Phase II hepatocellular carcinoma study European Pharmaceutical Review October 5, 2016
Advanced hepatocellular carcinoma (HCC)_"Yeliva is a sphingosine kinase-2 (SK2) selective inhibitor with anti-cancer and anti-inflammatory activities. By inhibiting the SK2 enzyme, yeliva blocks the synthesis of sphingosine 1-phosphate (S1P), a lipid signalling molecule that promotes cancer growth and pathological inflammation."
NICE recommends first drug for the Cancer Drugs Fund European Pharmaceutical Review October 4, 2016
"The National Institute for Health and Care Excellence (NICE) has issued final draft guidance which says osimertinib (Tagrisso, AstraZeneca) should be made available to some people with lung cancer through the Cancer Drugs Fund (CDF)."
Afatinib Dimaleate (inhibitor of the receptor tyrosine kinase (RTK)) with or without Cetuximab (Monoclonal antibodies)
ASTRO 2016: Three Novel Intrinsic Subtypes of Prostate Cancer Identified The ASCO Post : 9/28/2016
"Findings represent a step toward the implementation of personalized medicine in prostate cancer care."
Research provides new information on cancer and sugar-sweetened beverages link MedicalXpress October 3, 2016
"Sugar intake or sugar-sweetened beverage consumption has been demonstrated to have a positive association with obesity, diabetes and cardio-metabolic diseases, as well as some cancers."
Groundbreaking study sheds light on treating cancer ScienceDaily September 27, 2016
"The work by Prof. Tae-Hyuk Kwon (School of Natural Science) at Ulsan National Institute of Science and Technology (UNIST), South Korea has presented a new cancer treatment that uses red lights to target and kill cancer cells alternatively without surgery."
Smoking may affect DNA for more than 30 years, contributing to cancer and strokes Medical News Today Hannah Nichols 21 Sep 2016
"Smoking affects the human genome - a complete set of DNA in a person, including all genes - in the form of DNA methylation, finds a new study published in an American Heart Association journal Circulation: Cardiovascular Genetics. Some DNA methylation sites have been found to persist even after 30 years of quitting."
"Our study has found compelling evidence that smoking has a long-lasting impact on our molecular machinery, an impact that can last more than 30 years." Roby Joehanes, Ph.D., Harvard Medical School
Superiority results from the phase III OAK study comparing Tecentriq® to chemotherapy in a difficult to treat type of lung cancer (NSCLC) will be highlighted at the ESMO Presidential Symposium Oct 3, 2016
Apple a day cuts chance of five types of cancer MailOnline 28 September 2016
A review of over 40 previous studies: "Scientists from the University of Perugia found less tumours in fruit eaters - Biggest benefits were seen in cancers of the stomach and oesophagus - Apples are high in flavonoids, which are reduce the risk of getting cancer"
EryTech completes patient enrolment in Phase 2 pancreatic cancer trial European Pharceutical Review 28 September 2016
"EryTech Pharma, a French biopharmaceutical company developing ‘tumour starvation’ treatments for acute leukaemia and other oncology indications have enrolled their final patient in the Phase 2 trial of eryaspase, also known as graspa(r), for the treatment of pancreatic cancer."
Upfront Treatment Options for Squamous NSCLC OncLive Sep 22, 2016
Smoke gets in your genes GEN News Highlights Sep 22, 2016
"Researchers have now found that smoking actually leaves its "footprint" on the human genome in the form of DNA methylation, according to a new study ("Epigenetic Signatures of Cigarette Smoking") in Circulation: Cardiovascular Genetics.""They found that smoking-associated DNA methylation sites were associated with more than 7000 genes, or one-third of known human genes."
FDA Gives Niraparib Fast Track Designation for Ovarian Cancer Targeted Oncology September 19, 2016
Bristol-Myers to test Opdivo with Nektar drug for several cancers Reuters Sep 27, 2016
Lung cancer: Stage III NSCLC — is it time to centralize care? Nature Reviews Clinical Oncology Sept 27, 2016
Kite climbs after PhII data tee up FDA filing for CAR-T FierceBiotech Nick Paul Taylor Sep 27, 2016
The latest cancer treatment ‘revolution’ is separating hope from hype STAT Damian Garde September 27, 2016
"There’s new hope that a much-hyped-class of immunotherapies could revolutionize cancer treatment: Data released this week from an early test on patients stirred hope that the first such therapy could hit the market soon. But experts remain cautious about safety and efficacy — and warn that big questions remain."
Novel cancer treatment from Kite Pharma notches positive results, but big questions remain STAT Damian Garde September 26, 2016
Regression of Clubbing after Treatment of Lung Cancer N Engl J Med 2016, 375, 1171
"Transbronchial biopsy revealed an undifferentiated non–small-cell cancer with positive immunohistochemical staining for tumor protein 63 and cytokeratin 5/6, findings that were consistent with a diagnosis of poorly differentiated squamous-cell lung cancer. The patient was treated with carboplatin and paclitaxel chemotherapy and radiation therapy, and she was enrolled in an immunotherapy trial with a programmed death ligand 1 (PD-L1) inhibitor as maintenance therapy. Six months after diagnosis and the initiation of treatment, the patient noticed that the clubbing of her fingers had diminished (Panel C) and that she was no longer short of breath. A follow-up computed tomographic scan showed a decrease in the size of the mass (Panel D)."
Ceritinib Improves Progression-Free Survival in ALK+ NSCLC Targeted Oncology September 26, 2016
From CARTs To Checkpoints, Here's What's Coming In Immuno-Oncology Forbes arlene Weintraub Sept.27, 2016
Cigarette smoking has broad impact on human genome ecancernews Sept 27, 2016
The proof’s in the (black) pudding. Red meat, and especially processed meat, have been linked to bowel cancer Cancer Research UK, Sept 2016
Norwegian Study Shows Benefit of Aspirin as Secondary Prevention in Patients With Colorectal Cancer The ASCO Post 06/15/2016
The Most Functional Foods in the World Which Destroy Cancer Cells NaturalNews.com June 8, 2015
Therapeutic targeting of splicing in cancer Nature 2016 07 September 2016
Sticky nanoparticles could deliver drugs to fight ovarian and uterine cancers Yale News September 19, 2016
New ionic checkpoint that blocks T-cell function in tumours identified Nature 537, 539-543, 2016
"These results uncover an ionic checkpoint that blocks T cell function in tumours and identify potential new strategies for cancer immunotherapy."
Circulating and disseminated tumour cells — mechanisms of immune surveillance and escape Nature Reviews Clinical Oncology Sept 20, 2016
"Metastatic spread of tumour cells is the main cause of cancer-related deaths. Understanding the mechanisms of tumour-cell dissemination has, therefore, become an important focus for cancer research."
microRNA Therapeutics in Cancer — An Emerging Concept EBioMedicine September 20, 2016
"Highlights (1) miRNAs can act as oncogenes or tumor suppressors depending on the specific tissue/cancer targets. (2) miRNAs can be used as drugs or can be targets for drugs. (3) Clinical trials using miRNA mimetics or anti-miRNAs as therapeutic targets are currently underway and show promising results."
"The European Commission has approved Ibsen’s cabometyx (cabozantinib) 20, 40, 60 mg tablets for the treatment of advanced renal cell carcinoma (RCC) in adults following prior vascular endothelial growth factor (VEGF)-targeted therapy."
BET Bromodomain Inhibition Promotes Anti-tumor Immunity by Suppressing PD-L1 Expression Cell Reports Volume 16, Issue 11, p2829–2837, 13 September 2016
"Restoration of anti-tumor immunity by blocking PD-L1 signaling through the use of antibodies has proven to be beneficial in cancer therapy. Here, we show that BET bromodomain inhibition suppresses PD-L1 expression and limits tumor progression in ovarian cancer."
Un guide en français sur le cancerdupoumon non à petites cellules European Society for Medical Oncology 2016
Liquid biopsy better option for advanced lungcancer patients GEN News Highlights Sep 12, 2016
"The ACC researchers studied non-small-cell lung cancer (NSCLC) and were able to detect mutations from liquid biopsy blood samples that analyzed cell-free circulating tumor DNA (ctDNA). The scientists found that the mutations picked up by the liquid biopsy samples closely paralleled mutations from tissue biopsies identified using next-generation sequencing (NGS) tests, such as epidermal growth factor receptor (EGFR), tumor protein 53 (TP53), and anaplastic lymphoma kinase (ALK)."
FDA Grants Orphan Drug Designation to CD4CAR for the Treatment of Peripheral T-Cell Lymphoma The ASCO Post September 10, 2016
Experimental drug could stop melanoma, other cancers, research suggests Science Magazine Sept 7, 2016
Traitement du cancer du poumon non à petites cellules récidivant Canadian Cancer Society
RB1 deficiency in triple-negative breast cancer induces mitochondrial protein translation J. Clin. Invest. Aug 29, 2016
Retinoic acid suppresses colorectal cancer development Stanford News Center Aug 30, 2016
70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer N Engl J Med 2016, Aug 25, 2016
Gene test can reduce chemo use among breast-cancer patients, study says The Washington Post August 24
Experimental cancer therapy holds great promise — but at great cost STAT August 23, 2016
Gene activity linked to breast cancer survival European Pharmaceutical Review 18 August 2016
Acute myeloid leukaemia drugs market Nature Reviews Drug Discovery 15, 527-528 (2016)
The Microbiome of Aseptically Collected Human Breast Tissue in Benign and Malignant Disease Scientific Reports 6, 03 August 2016
Chimeric Antigen Receptor T cells for B Cell Neoplasms: Choose the Right CAR for You Curr Hematol Malig Rep. 2016 Jul 30
788 new cancer biomarkers discovered ecancernews 03 Aug 2016
"Researchers from the Universities of Sheffield, Coventry, and Warwick have identified 788 biomarkers from studies conducted over the past five years — compiling a comprehensive list of cancer signatures that could speed diagnosis and treatment."
Scientists discover new therapeutic target for lung cancer driven by KRAS ecancernews 29 Jul 2016
Mitochondria and Cancer Cell Volume 166, Issue 3, p555–566, 28 July 2016
Why working the night shift can pose a cancer risk MIT News July 28, 2016
New study reveals a link between circadian clock disruption and tumor growth.
All e-cigarettes emit harmful chemicals, but some emit more than others ecancernews 28 Jul 2016
Small-Molecule Procaspase-3 Activation Sensitizes Cancer to Treatment with Diverse Chemotherapeutics ACS Cent. Sci., July 25, 2016
Protein Central to Immune System Avoidance for Brain Cancer Identified GEN News Highlights Jul 25, 2016
Defining Metastatic Cell Latency N Engl J Med 2016, 375, 280-282
Toxicity and management in CAR T-cell therapy Molecular Therapy — Oncolytics 3, 16011 (2016)
New compounds defeat multi-drug resistant cancer cells MNT 15 July 2016
UPDATED: FDA halts Juno CAR-T trial after three patient deaths FierceBiotech Jul 7, 2016
Researchers generate elegant way of pinpointing how a new drug exerts beneficial effects Phys Org July 5, 2016
How liquid aspirin could kill brain tumours BBC News 28 June 2016
How liquid aspirin could kill brain tumours YouTube 28 juin 2016
"Describing their findings as "potentially groundbreaking" for future treatments of brain tumors, Prof. Geoff Pilkington and Dr. Richard Hill explain their new drug is able to cross the blood-brain barrier.""The new soluble drug - called IP1867B - combines aspirin and two other ingredients. The Portsmouth team developed it in collaboration with Innovate Pharmaceuticals."
Gene signature in ovarian cancer predicts survival and offers new drug target MedicalXpress June 28, 2016
Cancer-causing virus mimics host signal to drive cell growth, protein production Phys Org June 27, 2016
Probing the Melanoma Genome Reveals New Targets and Challenges OncLive June 17, 2016
First-in-Human CRISPR Immunotherapy Would Target PD-1 OncLive Jun 24, 2016
Identification of Circulating Tumor DNA for the Early Detection of Small-cell Lung Cancer EBioMedicine 25 June 2016
Nanoparticles used to deliver RNAi agents to thyroid cancer tumours drug target review 20 June 2016
FDA Approves First Liquid Biopsy Test for Lung Cancer Patients AACR June 6, 2016
Cancer : la promesse des "biopsies liquides" Science et Avenir 18-06-2016
Harms of Cigarette Smoking and Health Benefits of Quitting NIH NCI
What Are the Side Effects of Immunotherapy? DANA-FARBER February 10, 2016
How Scientists Aim to Expand Immunotherapy Options for Cancer Patients DANA-FARBER April 14, 2016
E-cigarette use results in suppression of immune and inflammatory-response genes in nasal epithelial cells similar to cigarette smoke American Journal of Physiology - Lung Cellular and Molecular Physiology Published 10 June 2016
Long-Term Data Shows Continued Benefit With Opdivo in Lung Cancer Cure Magazine June 14, 2016
"These results give us confirmation that the drug (Opdivo (nivolumab)) is active and that patients do truly benefit from immunotherapy."
Activité confirmée de Opdivo (Immunothérapie) dans le Cancer du Poumon Non à Petites Cellules (NSCLC)
Prostate Cancer Cancer Research Institute
Immunotherapy for Prostate Cancer - Therapeutic Vaccines - Oncolytic Virus Therapy - Checkpoint Inhibitors - Adoptive Cell Therapy - Adjuvant Immunotherapies
"Globally, there are approximately 1,100,000 new cases and 300,000 mortalities every year, comprising nearly 4 percent of all cancer deaths. It is estimated that 1 in every 6 men will be diagnosed with the disease during his lifetime."
A BH3 Mimetic for Killing Cancer Cells Cell 16 June 2016
"There are ~650,000 protein-protein interactions in the body But only 1 new drug targets them" Eric Topol
The new drug is Venetoclax, a BH3 mimetic approved for treating chronic lymphocytic leukemia
Scientists have proposed the first-ever use of the gene-editing technology CRISPR in humans By Sharon Begley STAT June 16, 2016
Meet one of the world's most groundbreaking scientists: "CRISPR" STAT November 6, 2015
CRISPR Systems Santa Cruz Biotechnology
Breast Cancer: KOL Insight - FirstWord 2016
Targeted therapies deliver on promise to transform breast cancer treatment
Targeted therapies continue to transform breast cancer treatment—branching out into new settings, targeting new patient populations, and in some cases upending entire treatment algorithms. Which ones will have the biggest impact on the market as pipeline drugs gain approval?
Find out in FirstWord’s new report, KOL Insight: Breast Cancer.
Packed with insights from 12 key opinion leaders (KOLs) in North America and Europe, the report covers 22 treatments (6 currently marketed and 16 in the pipeline) for 3 major types of breast cancer:
HER2+: Discover which clinical trials will decide whether established drugs are approved for use in new settings.
HER2-/HR+: Learn how dethroning the dominant drug has ushered in a new era of competition and innovation
Triple-negative (TNBC): The first targeted therapies are nearing approval. Find out which patients will benefit first.
“In breast cancer, we are at the helm of trying to identify who is going to benefit.”
- US KOL
Resisting Resistance: Targeted Therapies in Lung Cancer Trends in Cancer June 2016
"These approaches hold the promise of truly transforming cancer treatment and prolonging patients’ lives."
New Mechanism Triggers the Immune System to Attack Tumor Cells TheScienceExplorer June 2016
"The new function of STAT1 can be a decisive factor for cancer immunotherapy says Veronika Sexl."
See: Putz, E.M., A. Majoros, D. Gotthardt, M. Prchal-Murphy, E.M. Zebedin-Brandl, D.A. Fux, A. Schlattl, R.D. Schreiber, S. Carotta, M. Müller, C. Gerner, T. Decker, V. Sexl. Novel non-canonical role of STAT1 in natural killer cell cytotoxicity. OncoImmunology, 2016
Tumors have found a bloody new way to grow and spread Targeted Oncology June 14, 2016
Proof of concept for Notch-targetting cancer drugs ecancernews June 16, 2016
"A recent study has identified a small-molecule inhibitor of the Notch pathway, paving the way for a potential new class of personalised cancer medicines."
"The study was published online in the journal Cancer Research"
Fatty acid metabolism—the first trigger for cachexia? Nature Medecine June 2016, 22, 584-585
David A Sassoon "A recent study shows that skeletal muscle responds to tumor-secreted factors by undergoing a change in fatty acid metabolism, and that blocking this metabolic response in mice inhibits muscle wasting."
Excessive fatty acid oxidation induces muscle atrophy in cancer cachexia Nature Medecine June 2016, 22, 666-672
Combination immunotherapy treatment for melanoma given NHS approval Cancer Research UK 17 June 2016
"The National Institute for Health and Care Excellence (NICE) has approved the combination therapy of nivolumab (Opdivo) and ipilimumab (Yervoy) for people with melanoma that has spread around the body."
Tumors have found a bloody new way to grow and spread By Mitch Leslie Science Jun. 16, 2016
Tumors' do-it-yourself blood vessels Mitch Leslie Science 17 Jun 2016: Vol. 352, Issue 6292, pp. 1381-1383
Une clé en cancérologie : l'apport sanguin à la tumeur
Starving cancer cells by blocking their metabolism MedicalXpress June 14, 2016
Pan Xu et al, LRH-1-dependent programming of mitochondrial glutamine processing drives liver cancer, Genes & Development (2016)
"Inhibiting LRH-1 can thus be an effective way to starve only liver cancer cells, while leaving normal cells intact," says Kristina Schoonjans (EPFL). Her lab is now actively trying to identify new chemotherapeutic agents to treat liver cancer by developing specific compounds that inhibit LRH-1. The researchers also hope that these findings may extend to other types of cancer, since LRH-1 is also abundant in the pancreas and ovaries."
Novel radioimmunotherapy results in complete remission in preclinical colorectal cancer study Drug Target Review 13 June 2016
"Researchers have unveiled a novel radioimmunotherapy that combines a cancer-seeking antibody with potent radionuclide agents, resulting in complete remission of colorectal cancer in mouse models."
Gene therapy's out-of-body experience Nature Biotechnology 2016
"With an approval likely at the EMA, ex vivo gene therapy in hematopoietic stem cells appears poised for prime time."
BreakingNews Results from a clinical trial in relapsed & refractory acute lymphoblastic June 12, 2016:
The two-year OS rate for inotuzumab ozogamicin was 23 percent (95% CI, 16%‒30%) compared to chemotherapy at 10 percent (95% CI, 5%‒16%).
“Adult patients with relapsed or refractory ALL have a five-year survival rate of less than 10 percent, making these patients particularly difficult to treat. To see remission rates and two-year survival rates that are more than doubled compared to standard of care chemotherapy is very gratifying. We believe these data add to the growing body of evidence that supports inotuzumab ozogamicin as an important potential treatment option in adults with relapsed or refractory ALL,” said Mace Rothenberg, MD, Chief Development Officer, Oncology, Pfizer Global Product Development.
CAR Therapy Yields High Complete Response Rates in Adults with B-cell ALL in Phase I Trial Targeted Oncology June 9, 2016
"It's important to note that we observed high CR and MRD-CR rates regardless of patients' pre-infusion disease burden. And patients with minimal disease at the time of 19-28z CAR T-cell infusion experienced significantly less severe CRS and neurological toxicities.... These findings support the use of 19-28z CAR T-cells in earlier lines of ALL treatment, such as in a frontline setting."—Jae H. Park, MD
Optimal Sequencing in Squamous Non-Small Cell Lung Cancer OncLive Jun 08, 2016
"While Amgen has long been recognized for its strength in developing biologic medicines, our expertise also extends to the field of small molecule drug design. The elegant science applied to a tough cancer target exemplifies this new capability"
1. Efeyan, Alejo, and Manuel Serrano. "p53: guardian of the genome and policeman of the oncogenes." Cell cycle 6.9 (2007): 1006-1010.
2. Crawford, L. V., et al. "Detection of a common feature in several human tumor cell lines--a 53,000-dalton protein." Proceedings of the National Academy of Sciences 78.1 (1981): 41-45.
3. Prives, Carol. "Signaling to p53: breaking the MDM2–p53 circuit." Cell 95.1 (1998): 5-8.
4. Rew, Yosup, et al. "Structure-based design of novel inhibitors of the MDM2–p53 interaction." Journal of medicinal chemistry 55.11 (2012): 4936-4954.
5. Bernard, Denzil, Yujun Zhao, and Shaomeng Wang. "AM-8553: a novel MDM2 inhibitor with a promising outlook for potential clinical development." Journal of medicinal chemistry 55.11 (2012): 4934-4935.
Laser ablation becomes increasingly viable treatment for prostate cancer EurekAlert June 10, 2016
"The technique uses magnetic resonance imaging, or MRI, to guide the insertion of a laser fiber into cancerous tumors. When heated, the laser destroys the cancerous tissue."
New liquid biopsy techniques at the bleeding edge of cancer MedicalXpress June 10, 2016 by John Hewitt
"Liquid Biopsy: Source of liquid biopsy tumor material. Solid tumor masses may shed (1) circulating tumor DNA (ctDNA) and circulating tumor RNA (ctRNA), (2) apoptotic circulating tumor cells (CTCs), or (3) intact CTCs into the circulation. In addition, ctDNA and ctRNA may enter the bloodstream after apoptosis of circulating and noncirculating tumor cells (4). Credit: H. McDonald / Science Translational Medicine"
ChemoFilter - the sponge designed to soak up cancer drugs Drug Target Review 7 June 2016
Immunotherapy & Chemotherapy: What's the Difference CRI June 2016
Le Cance de la Vessie : Les Faits Roche 5 Juin 2016
Nanobots are waiting in the wings to cure cancer and clean up ocean pollution MarketWatch June 9, 2016
"a potential prognostic biomarker in cutaneous sporadic melanoma"
Dabrafenib/Trametinib Combo Highly Effective in BRAF-Mutant NSCLC OncLive Jun 06, 2016
Progrès dans le traitement du cancer du pancréas Drug combination may extend pancreas cancer survival, trial finds The Guardian June 3, 2016
"Liverpool University-led study found mix of two off-patent drugs upped five-year survival rate from 16% to 29% of patients"
Study reveals insights into protein linked to cancer and Alzheimer's disease Phys Org June 6, 2016
"There's recent evidence suggesting that people more susceptible to certain cancers are less likely to develop Alzheimer's disease, and vice versa," Peng said. "This makes sense given that both diseases depend on signals driven by Pin1 interacting with other proteins."
Please see, Xingsheng Wang et al. Negative Regulation of Peptidyl-Prolyl Isomerase Activity by Interdomain Contact in Human Pin1, Structure (2015)
A Blood Test for Cancer Gets Closer TIME June 4, 2016
Saturday at ASCO: Liquid Biopsy Matches Tissue Biopsy Medscape June 04, 2016
Immuno-oncology: A Great Promise for Patients & Investors By Skye Drynan Capital Group Equity Analyst
New drug 'retrains' immune system to fight aggressive bladder cancer EurekAlert June 5, 2016 - "Cancer de la vessie : la percée de l'atezolizumab"
"Cette molécule réduit de 30% la taille de la tumeur et freine la croissance de cette masse cancéreuse chez 24% des patients"
What does cancer look like up close? National Cancer Inst - cancer close up = 1844 images
Novel Protein Agent Targets Cancer and Host of Other Diseases GEN News Highlights Jun 1, 2016
"This integrin pair, v3, is not expressed in high levels in normal tissue,"
Researchers find up to one-quarter of lung cancer patients ineligible for immunotherapy MedicalXpress June 4, 2016 & Journal reference: JAMA Oncology
"The researchers studied 210,509 lung cancer patients over age 65 and applied two different algorithms to measure the presence of an autoimmune disease. The most common autoimmune diseases reported were rheumatoid arthritis, psoriasis, and polymyalgia rheumatica."
Visualizing Clonal Evolution in Cancer Molecular Cell Volume 62, Issue 5, p652–656, 2 June 2016
"Rapid and inexpensive single-cell sequencing is driving new visualizations of cancer instability and evolution."
New metabolic pathway illustrates salicylic acid’s anti-cancer capabilities GEN News Highlights Jun 1, 2016
"In a study (“Salicylate, Diflunisal and Their Metabolites Inhibit CBP/p300 and Exhibit Anticancer Activity”) published in eLife, the investigators discovered that both salicylic acid and diflunisal suppress two key proteins that help control gene expression throughout the body."
Bending HER2 receptors to kill off invasive breast cancer Drug Target Review 3 June 2016
Vers un vaccin universel contre le cancer ? Scientists trick body's viral response to combat cancer MedicalXpress June 1, 2016
"The new treatment is called an RNA vaccine—it works just like a preventive vaccine by mimicking an infectious agent and training the body to respond to it."
Comment marche en théorie le nouveau type de vaccin universel contre le cancer Le HuffPost 01/06/2016
Many different types of immunotherapy are used to treat cancer National Cancer Inst
The future of patient-centred cancer care and research YouTube Roche May 18, 2016
Evidence for the role of microRNA 374b in acquired cisplatin resistance in pancreatic cancer cells Cancer Gene Therapy advance online publication 27 May 2016
Restoring chemotherapy sensitivity in resistant pancreatic cancer Drug Target Review 27 May 2016
"By increasing the level of a specific microRNA (miRNA), Georgia Institute of Technology researchers have restored chemotherapy sensitivity in vitro to a line of human pancreatic cancer cells that had developed resistance to a common treatment drug."
Cell phones and rats: Study explores radiation exposure May 28, 2016 by Nancy Owano
"According to the Scientific American report, the study chronicled rodents subjected to a lifetime of electromagnetic radiation starting in utero. The animals exposed to RF had a greater chance of being diagnosed with malignant glioma type of brain cancer, as well as developing a tumor found on the heart. "The incidence grew with greater levels of exposure to the radiation. Some of the rats had glioma—a tumor of the glial cells in the brain —or schwannoma of the heart," said Maron." (The two tumor types, malignant gliomas of the brain and schwannomas of the heart were the focus.)
Safety of PD-1 Inhibitors in Squamous NSCLC OncLive May 23, 2016
Fighting Cancer with Borrowed Immunity GEN News Highlights May 23, 2016
"the healthy donors’ T cells could be used to broaden the T-cell receptor repertoires of the cancer patients’ T cells."
"The approach was detailed in a paper that appeared May 19 in the journal Science, in an article entitled, “Targeting of Cancer Neoantigens with Donor-Derived T Cell Receptor Repertoires.”
Prévention cancers LE TEST - 3 min pour faire le point - Institut National du Cancer
Cancer Vaccines NCI Reviewed: December 18, 2015 - What types of vaccines are being studied in clinical trials? - Active Clinical Trials of Cancer Treatment Vaccines by Type of Cancer
We’re building a brain tumour by Nick Hall May 26, 2016
"A team at Heriot Watt University in Edinburgh is about to use a 3D bioprinter to build a brain tumour."
NIH study visualizes proteins involved in cancer cell metabolism NCI May 26, 2016
“These advances demonstrate a real-life scenario in which drug developers now could potentially use cryo-EM to tweak drugs by actually observing the effects of varying drug structure— much like an explorer mapping the shoreline to find the best place to dock a boat — and alter its activity for a therapeutic effect,” said Doug Lowy, M.D., acting director, NCI."
Merk A, Bartesaghi A, Banerjee S, Falconieri V, Rao P, Davis M, Pragani R, Boxer M., Earl LA, Milne, JLS, Subramaniam, S. Breaking cryo-EM resolution barriers to facilitate drug discovery. Cell. Online May 26, 2016.
“It is exciting to be able to use cryo-EM to visualize structures of complexes of potential drug candidates at such a high level of detail,” said Subramaniam
Scientists block breast cancer cells from hiding in bones ecancernews May 25, 2016 and Science Translational Medicine 2016
"Clinical studies have found that breast cancer can be caught early and treated, and patients can have no signs of disease," said Dorothy A. Sipkins, M.D., Ph.D., associate professor in the division of haematological malignancies and cellular therapy at Duke. "And then five, 10 or even 15 years later, a patient can relapse. Most often, the site of the metastasised cancer is in the bone."
"One strategy is finding a way to inhibit E-selectin, which could limit the cancer's ability to travel into the bone and resurge as metastatic cancer"
Science Translational Medicine 25 May 2016 Vol. 8, Issue 340, pp. 340ra73
Characterization of Molecular Differences in Cancer Between Male and Female Patients The ASCO Post 5/20/2016
"The research revealed two cancer-type groups associated with cancer incidence and mortality, suggesting a “pressing need” to develop sex-specific therapeutic strategies for some cancers. The research findings were published by Yuan et al in Cancer Cell."
Nontoxic Method for Treating Cancer Reportedly Developed GEN News Highlights May 19, 2016 (vide infra)
Keywords: 2-deoxy-D-glucose, fenofibrate, energy stress, mTOR, eIF2α
Une méthode non toxique pour traiter le cancer aurait été développée: "Combining 2-Deoxy-D-Glucose with Fenofibrate"
Exercise Lowers Risk for These 13 Cancer Types NBC NEWS May 16 2016
Association of Leisure-Time Physical Activity With Risk of 26 Types of Cancer in 1.44 Million Adults JAMA Internal Medicine May 16 2016
The Cancer Almanac The New york Times Magazine By RYAN BRADLEY MAY 12, 2016
Vitamin E a potential biomarker for development of brain tumours ecancernews May 20, 2016
High levels of protein p62 predict liver cancer recurrence ecancernews May 19 2016
Where we stand now: E-cigarettes By Sandee LaMotte, CNN May 5, 2016
Medical Illustration: Non-Small Cell Lung Cancer APRIL 23, 2016
Gene-Editing Technique Improves Immunotherapy GEN News Highlights Apr 18, 2016
Prostate cancer and diets April 17, 2016
Cancer cells turn healthy cells to the ‘dark side’ April 14, 2016
"Cancer cells use a mutant gene to coerce neighbouring healthy tissue into helping with the disease’s growth and spread, a major new study reports."..."Scientists at The Institute of Cancer Research, London, and the Cancer Research UK Manchester Institute based at The University of Manchester found that faulty versions of the KRAS gene – often mutated in cancer – can have an important effect on healthy tissue." Cell 2016
Dressed to kill: Tailoring a suit for tumour-penetrating cancer meds ecancernews Apr 11, 2016
"In the paper entitled "Hyaluronidase Embedded in Nanocarrier PEG Shell for Enhanced Tumor Penetration and Highly Efficient Antitumor Efficacy," the group reports that their method is four times more effective at sending nanoparticles into a solid tumour than one of the best strategies currently in use." Nano Letters 2016
Des centaines de produits ménagers jugés toxiques Le Figaro 11/04/2016
"L'association 60 millions de consommateurs publie une «liste noire» d'une vingtaine de substances toxiques présentes dans les produits d'entretien et dont la mention est obligatoire. Mais l'association rappelle que plus de 80 autres substances allergènes ont été identifiées."
10 Things Cancer Experts Do To Avoid Getting The Disease Prevention April 21, 2016 by Hallie Levine
10 Cancer Symptoms Most People Ignore Prevention December 12, 2014 By Kristen Fischer
"The new study, published in the Journal of the National Cancer Institute, is the first to show that tumours can become resistant to drugs over time by learning to steal normal blood vessels from surrounding tissue – a process that researchers call vessel co-option." Journal of the National Cancer Institute 2016
"Abstract: The MYC oncogene codes for a transcription factor that is overexpressed in many human cancers. Here we show that MYC regulates the expression of two immune checkpoint proteins on the tumor cell surface, the innate immune regulator, CD47 (Cluster of Differentiation 47) and the adaptive immune checkpoint, PD-L1 (programmed death-ligand 1). Suppression of MYC in mouse tumors and human tumor cells caused a reduction in the levels of CD47 and PD-L1 mRNA and protein. MYC was found to bind directly to the promoters of the CD47 and PD-L1 genes. MYC inactivation in mouse tumors down-regulated CD47 and PD-L1 expression and enhanced the anti-tumor immune response. In contrast, when MYC was inactivated in tumors with enforced expression of CD47 or PD-L1, the immune response was suppressed and tumors continued to grow. Thus MYC appears to initiate and maintain tumorigenesis in part through the modulation of immune regulatory molecules." Source: Science 10 march 2016
Breakthrough allows drug delivery for brain diseases, cancers MedicalXpress April 5, 2016
Newly discovered clues to the cause of chemoresistance in small cell lung cancer MedicalXpress April 4, 2016
Immunotherapy Ideal Across All Settings for NSCLC Targeted Oncology April 1, 2016
An injectable nanoparticle generator enhances delivery of cancer therapeutics Nat Biotechnol 2016,34, 414-418
PTEN enables the development of pre-B acute lymphoblastic leukemia Nature Medecine 2016, 22, 339-340
Can We Treat Colorectal Cancer With Immunotherapy? AACR March 10, 2016
Biomarker expression may predict metastasis in uveal melanoma HemOnc Today March 1, 2016
"High levels of PRAME mRNA appeared associated with increased metastasis risk among patients with class 1 uveal melanoma, according to study results published in Clinical Cancer Research."
PRAME as an Independent Biomarker for Metastasis in Uveal Melanoma Clin Cancer Res 2016
New immunotherapy discovery could give treatments the precision they need Cancer Research UK March 3, 2016
Predictive proteins: Elevated levels trigger metastatic progression of cancer cells ecancernews March 1, 2016
"The discovery suggests GEFs (guanine nucleotide exchange factors) offer a new and more precise indicator of disease state and prognosis.""We found that elevated expression of each GEF is associated with a shorter, progression-free survival in patients with metastatic colorectal cancer," said Ghosh.
Skin Cells Transformed into Brain Tumor-Hunting Stem Cells MDT february 29, 2016
High-fat diet enhances stemness and tumorigenicity of intestinal progenitors Nature 2016, 216, 53-58
Researchers make cancer immunotherapy ‘breakthrough’ European Pharmaceutical Review March 2016
New immunotherapy discovery could give treatments the precision they need Cancer Research UK March 2016
Driving CAR T-cells forward Nature Reviews Clinical Oncology 2016
Researchers link lipids to one third of myelomas YaleNews February 10, 2016
"Yale Cancer Center researchers have identified a link between lipids and the origin of a third of all myelomas, a type of cancer affecting plasma cells. The findings, published Feb. 10 in the New England Journal of Medicine, could fundamentally change the way this cancer and others are treated."
'Extraordinary' treatment could be cancer breakthrough February 16, 2016
Cancer statistics, 2016 CA Cancer J Clin 2016, 7–30
New Saliva Test May Be Able To Detect Cancer In Just 10 Minutes IFLSCIENCE February 16, 2016
Phoenix et al., Medulloblastoma genotype dictates blood brain barrier phenotype. Cancer Cell, 2016
Clinical Cancer Research 2016 DOI: 10.1158/1078-0432.CCR-15-2308
"The study shows that in glioblastoma (GBM), the essential amino acids methionine and tryptophan are abnormally metabolized due to the loss of key enzymes in GBM cells."
An injectable nanoparticle generator enhances delivery of cancer therapeutics Nature Biotechnology 2016
Injectable nanoparticle generator could radically transform metastatic cancer treatment eCancer News March 2016
Three-Biomarker Score More Accurately Predicts Ovarian Cancer Outcomes Targeted Oncology Wed March 23, 2016
JAMA Oncol. Published online March 24, 2016. doi:10.1001/jamaoncol.2015.6275
Cancer Volume 122, Issue 5, pages 722–729, March 1, 2016
'Extraordinary' treatment could be cancer breakthrough ITV News Science February 2016
"Together, these results link exercise, epinephrine, and IL-6 to NK cell mobilization and redistribution, and ultimately to control of tumor growth."
Cell Metabolism 2016, 23, 554-562
How does alcohol cause cancer? Cancer Research UK by Aine McCarthy February 9, 2016
Reports Clinical Cancer Advances 2016 Journal of Clinical Oncology Feb 4, 2016
Tweaking Mother Nature, biologists aim for better cancer-fighting cells STAT January 28, 2016
Vaccine Strategy for Biomarker in NSCLC Reaches Phase III Study OncLive January 27, 2016
How Exercise May Lower Cancer Risk February 24, 2016
"Study finds cola boosts effectiveness of Tarceva for patients who are also taking a heartburn medicine" by E J Mundell WebMD News from HealthDay February 12, 2016
Cancer treatment: Therapeutic approach gives hope for the treatment of multiple myeloma EurekAlert February 5, 2016
Aspirin Use May Lower Risk of Developing Lethal Prostate Cancer Cure January 12, 2016
Regular aspirin intake reduces risk for lethal prostate cancer HemoOnco Today January 5, 2016
“It is premature to recommend aspirin for prevention of lethal prostate cancer, but men with prostate cancer who may already benefit from aspirin’s cardiovascular effects could have one more reason to consider regular aspirin use,” Christopher Brian Allard, MD, urologic oncology fellow at Brigham and Women’s Hospital and Massachusetts General Hospital, as well as instructor in surgery at Harvard Medical School, said in a press release."
Reference: Allard CB, et al. Abstract 306. Presented at: Genitourinary Cancers Symposium; January 7-9, 2016; San Francisco.
Breast cancer detection rate using ultrasound is shown to be comparable to mammography ecancernews January 4 2016
"The use of ultrasound (US) in detecting breast cancer has been shown to be comparable in its sensitivity to that of mammography and should be considered when testing for the disease according to a study published in the JNCI"
A Designed Inhibitor of p53 Aggregation Rescues p53 Tumor Suppression in Ovarian Carcinomas Cancer Cell Volume 29, Issue 1, p90–103, 11 January 2016
"We designed the peptide ReACp53 to halt aggregation of p53 in cells"
SELECTED ONCOLOGY PUBLICATIONS 2015
2015 In Review: New drug approvals – the FDA hits a 19 year-record by Simon King December 23, 2015
Few cancer drugs demonstrate OS benefit at time of FDA approval HemOnc Today December 30, 2015
"Chul Kim, MD, MPH, clinical fellow in the medical oncology branch of the NCI, and Vinay Prasad, MD, MPH, assistant professor of medicine at Oregon Health Sciences University, found that 86% of these drugs approved based on surrogate endpoints had unknown effects on OS or had failed to show an OS improvement after several years of follow-up." Kim C and Prasad V. JAMA Intern Med. 2015
Fast and Furious: Melanoma Research in 2015 Dec 28, 2015
Cellectis CEO: Creating A Cancer Fighting Machine Mad Money CNBC Dec 23, 2015
Pfizer snags U.S. rights to Cellectis' white-hot CAR-T therapy by Nick Paul Taylor Nov 19, 2015 (UCART19)
Brain Cancers Reveal Novel Genetic Disruption in DNA The New York Times Dec 23, 2015
Insulator dysfunction and oncogene activation in IDH mutant gliomas Nature 2016, 529, 110-116
"Transformer" Proteins with Role in Cancer GEN News Highlights Dec 22, 2015
"The study (“Asymmetric Modulation of Protein Order-Disorder Transitions by Phosphorylation and Partner Binding”), published in Angewandte Chemie, focuses on the nucleophosmin (NPM1) protein, which has many functions and, when mutated, has been shown to interfere with cells' normal tumor suppressing ability. NPM1 has been implicated in cancers such as non-Hodgkin lymphoma and acute myelogenous leukemia."
Pembrolizumab Gains Two New Indications in Advanced Melanoma December 21, 2015
New Drug for Pediatric Neuroblastoma Shows Promise in Preclinical Studies NCI December 17, 2015
"An international team of scientists has identified a possible new treatment target for pediatric neuroblastoma. Based on promising findings in animal models, the team is planning an early-stage clinical trial of a drug that inhibits this target in children with neuroblastoma."Science Translational Medicine
Novel Prostate Cancer Biomarkers Dec 16, 2015
Mol. Cancer Res. 2015, 14, 241–252
Top 5 Cancer Immunotherapy Stories of 2015 Cancer Research Institute December 2015
Immune therapy drug results in prolonged survival in advanced lung cancer Yale News December 2015
Science 11 Dec 2015 Vol. 350, Issue 6266, pp. 1391-1396
Vitamin C halts aggressive colorectal cancer: study Cornell Chronicle November 2015
Response Rates Hover Around 100% for CAR T-cell Therapies in ALL Targeted Oncology 2015
Uridine Triacetate Approved by FDA to Deter Chemo Overdose and Toxicities Targeted Oncology 2015
Tina El Rayes et al. Lung inflammation promotes metastasis through neutrophil protease-mediated degradation of Tsp-1, Proceedings of the National Academy of Sciences (2015).
"To Slow Cancer’s Spread, Prevent Formation of Cell-Cell Bridges" GEN News Highlights 2015
“Physical nanoscale conduit-mediated communication between tumour cells and the endothelium modulates endothelial phenotype.” Nature Communications 2016
Precision Immunology: The Promise of Immunotherapy for the Treatment of Cancer Journal of Clinical Oncology 2015
"The scientists believe that the beneficial effect of aspirin in cancer is due to its antiplatelet effect. Platelets are a blood component whose function is to stop bleeding by clumping and clogging blood vessel injuries. Circulating tumor cells (CTCs) are thought to hide themselves from the immune system with the help of the clothing of platelets that surround them. Aspirin inhibits platelet function and therefore allows the immune system to recognize CTCs and eliminate them."
Cancer Immunotherapy: immune checkpoint inhibitors, cancer vaccines, and adoptive T-cell therapies Insight Pharma Reports 2014
Regeneron and Sanofi Launch Major New Immuno-Oncology Collaboration PRnewswire Jul 28, 2015
Remarkable Six Months for Treatment Options in NSCLC Targeted Oncology July 29,2015